α-Synuclein Assay

CN114341343BActive Publication Date: 2024-11-15CHASE THERAPEUTICS CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080032514.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-30
Filing Date
2020-04-30
Publication Date
2024-11-15
Estimated Expiration
2040-04-30

Smart Images

  • Figure CN114341343B_ABST
    Figure CN114341343B_ABST
Patent Text Reader

Abstract

The invention relates to an assay for alpha-synuclein and its various forms, comprising: a) providing a blood sample from a subject; b) isolating exosomes of central nervous system ("CNS") origin from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce washed exosomes; d) isolating the internal contents of the washed exosomes; e) determining in the isolated internal contents the quantitative measurement of oligomeric alpha-synuclein and one or more protein forms selected from the group consisting of monomeric alpha-synuclein, phosphorylated alpha-synuclein, monomeric tau, oligomeric ... f) separating species of oligomeric α-synuclein into more than one fraction; g) determining a quantitative measurement of each of one or more separated oligomeric α-synuclein species and optionally one or more species selected from the group consisting of monomeric α-synuclein, tau-synuclein copolymers, amyloid β-synuclein copolymers, and tau-amyloid β-synuclein copolymers.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Statement Regarding Federally Funded Research

[0002] none.

[0003] Citation of Related Applications

[0004] This application claims the benefit of the priority date of U.S. Provisional Application No. 62 / 841,118, filed on April 30, 2019, the contents of which are incorporated herein in their entirety.

[0005] background

[0006] Neurodegenerative diseases are characterized by degenerative changes in the brain, including loss of function and neuronal death. Neurodegenerative diseases include, but are not limited to, Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and Lewy body dementia.

[0007] Many neurodegenerative diseases are characterized by abnormal accumulation of oligomeric forms of proteins. It is believed that these oligomeric forms promote neuronal degeneration and death. In particular, Parkinson's disease is characterized by the accumulation of oligomeric forms of alpha synuclein. It has also been found that alpha synuclein can aggregate with other proteins such as tau and amyloid beta to form copolymers.

[0008] Overview of public content

[0009] refer to Figure 1, an assay for alpha synuclein includes the following operations: obtaining a blood sample from a subject (100). The blood sample can be processed to provide a blood fraction, such as a plasma sample. The blood sample is enriched for CNS-derived exosomes (e.g., CNS-derived exosomes are separated from the blood sample) (110). This can be a two-step operation, which includes, first, separating total exosomes (111), and second, enriching CNS-derived exosomes from total exosomes (112). Enriching the internal contents of the separated exosomes (120). This can include scrubbing to remove proteins attached to their surfaces (121). The internal contents of the exosomes are released for analysis (122). The analysis includes, first, determining a quantitative measurement of multiple protein forms in the exosomes (130). This includes at least measuring the amount of oligomeric alpha synuclein (e.g., total oligomeric alpha synuclein). Typically, it will also include measuring the amount of monomeric alpha synuclein. Tau and amyloid β can be combined with α-synuclein to form copolymers. Therefore, the measurement operation can also include measuring one or more forms of tau and / or amyloid β. The form of tau includes monomeric tau, oligomeric tau and phosphorylated tau. The form of amyloid β includes A-β1-40, A-β1-42 and oligomeric A-β. Oligomeric α-synuclein has different size categories. The oligomeric forms are graded or separated from each other (140). Then one or more oligomeric forms of α-synuclein are quantified (150). Determining the quantitative measurement can be accomplished by separating the forms from each other, such as by gel electrophoresis. Monomeric α-synuclein can also be determined in this operation. In addition to quantifying the amount of oligomeric α-synuclein, the form of α-synuclein associated with various forms of tau and / or amyloid β can also be detected.

[0010] Quantitative measurement of oligomeric alpha synuclein, alone or in combination with quantitative measurement of other forms discussed herein, such as monomeric alpha synuclein, tau and its forms, and amyloid beta and its forms, can be used in diagnostic tests to determine the presence or absence or progression of a synucleinopathy condition, or to determine the efficacy of a drug to alter the amount or relative amount of one or more forms of the protein described herein toward a normal amount.

[0011] Various methods for detecting oligomers of alpha-synuclein are described in international patent application PCT / US2018 / 066612 (“Methods for developing pharmaceuticals for treating neurodegenerative conditions”) filed on December 18, 2018, the contents of which are incorporated herein in their entirety.

[0012] Disclosed herein, inter alia, are biomarker profiles for neurodegenerative conditions, such as synuclein pathological conditions, amyloid pathological conditions, tauopathy, and Huntington's disease, and neurodegeneration associated therewith. In certain embodiments, the biomarker profile includes measurements of one or more different species (also referred to as "forms") of a neurodegenerative protein, such as alpha-synuclein, amyloid beta, tau, or huntingtin. The neurodegenerative protein profile may include quantitative measurements of each of one or more neurodegenerative protein forms selected from the following: (I) at least one oligomeric form; (II) more than one oligomeric form; (III) at least one oligomeric form and at least one monomeric form; (IV) more than one oligomeric form and at least one monomeric form; (V) at least one oligomeric form and more than one monomeric form; and (VI) more than one oligomeric form and more than one monomeric form.

[0013] Also disclosed herein are methods for developing drugs for treating neurodegenerative conditions, such as synuclein pathological conditions, amyloid conditions, tau pathological conditions, and Huntington's disease. The method includes using biomarkers to determine the effect of a candidate drug on the condition. The biomarker profile includes quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein is, for example, alpha-synuclein and amyloid beta, tau, or huntingtin. The biomarker profile includes one or more oligomeric forms and optionally one or more monomeric forms of the neurodegenerative protein. The neurodegenerative protein can be quantified from CNS-derived exosomes, such as from the blood of a subject.

[0014] In certain embodiments, protein species are measured from CNS-derived extracellular vesicles (hereinafter referred to as exosomes), for example, isolated from blood. The detected species may be derived from an internal compartment of an exosome, for example, from an exosome from which surface proteins have been removed. Biomarker profiles measured in this manner represent a relatively simple and non-invasive means of measurement.

[0015] Therefore, the methods of the present disclosure for measuring the biomarker profile of neurodegeneration can be used to test the neuroprotective efficacy of drug candidates in drug development, which are sometimes referred to as putative neuroprotectants herein. For example, the methods described herein can be used to further understand the downstream effects and molecular basis of oligomerization in neurodegenerative conditions such as synucleinopathy, and to accelerate the development of effective treatment strategies. Such methods can also be used to identify subjects for recruitment in clinical trials, and can be used to determine the diagnosis, prognosis, progression or risk of developing synucleinopathy conditions. Also provided herein are novel methods for treating subjects who are determined by the methods of the present disclosure to suffer from neurodegeneration associated with synucleinopathy conditions or are at risk of developing neurodegeneration associated with synucleinopathy conditions, particularly neuroprotective treatments.

[0016] Other objects of the present disclosure may be apparent to those skilled in the art after reading the following description and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] The novel features of the present disclosure are particularly set forth in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by referring to the following detailed description and the accompanying drawings, which set forth illustrative embodiments in which the principles of the present disclosure are utilized, wherein:

[0019] Figure 1 A flow chart showing an exemplary method of detecting monomeric and oligomeric forms of α-synuclein and distinguishing the oligomeric forms.

[0020] Figure 2 A flow chart showing an exemplary protocol for validating drug efficacy.

[0021] Figure 3 A flow chart showing an exemplary method for detecting monomeric and oligomeric forms of proteins involved in neurodegenerative conditions.

[0022] Figure 4 A flow chart showing an exemplary method for detecting monomeric and oligomeric forms of a neurodegenerative protein.

[0023] Figure 5 An exemplary flow chart for creating and validating a diagnostic model for diagnosing a neurodegenerative condition is shown.

[0024] Figure 6 An exemplary flow chart for classifying a subject according to any of several states by executing a diagnostic algorithm or model on a biomarker profile is shown.

[0025] Figure 7 An exemplary biomarker profile is shown, including monomeric species of alpha-synuclein and five oligomeric species of alpha-synuclein in five different states. Such a profile can be used to correlate with multiple states. The profile can be used by a human operator or by a model executed by a computer.

[0026] Details of public content

[0027] I. Neurodegenerative conditions and associated proteins

[0028] The methods disclosed herein can be used for diagnosis and drug development of a variety of neurodegenerative conditions. These include, but are not limited to, synuclein diseases (e.g., Parkinson's disease, Lewy body dementia, multiple system atrophy), amyloid diseases (e.g., Alzheimer's disease), tauopathies (e.g., Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration), and Huntington's disease. These diseases share in common the accumulation of toxic oligomeric polypeptide species and in some cases abnormally phosphorylated oligomeric or monomeric forms, as well as the ability to detect such forms in CNS-derived exosomes.

[0029] As used herein, the term "neurodegenerative protein" refers to a protein associated with neurodegeneration in an oligomeric form. Neurodegenerative proteins include, but are not limited to, α-synuclein, tau, amyloid β, and huntingtin.

[0030] It is believed that certain oligomeric forms or abnormal phosphorylated forms of brain polypeptides underlie a variety of neurodegenerative conditions. This includes, for example, the role of alpha-synuclein in synuclein pathological conditions, the role of amyloid beta in amyloid pathological conditions, the role of tau in tau pathological conditions, and the role of huntingtin in Huntington's disease. In particular, current evidence suggests that alpha-synuclein oligomers can act as toxic species in PD and other synuclein diseases. In certain embodiments, the oligomeric species detected are abnormally phosphorylated species.

[0031] A profile of the amount of each of one or more neurodegenerative protein forms (e.g., forms of α-synuclein, amyloid β, tau, or huntingtin) selected from (I) at least one oligomeric form; (II) more than one oligomeric form; (III) at least one oligomeric form and at least one monomeric form; (IV) more than one oligomeric form and at least one monomeric form; (V) at least one oligomeric form and more than one monomeric form; and (VI) more than one oligomeric form is used in a model, particularly for inferring a neurodegenerative condition or progression to a neurodegenerative condition, typically with the one or more oligomeric forms included in the model indicating the presence and activity of a disease or progression to a disease. This includes an increase in the relative amount of oligomeric alpha-synuclein forms, which indicates the presence and activity of a synuclein disease or the progression to a synuclein disease; an increase in the relative amount of oligomeric amyloid beta, which indicates the presence and activity of an amyloid disease or the progression to an amyloid disease; an increase in the relative amount of oligomeric or abnormally phosphorylated tau, which indicates the presence and activity of a tau disease or the progression to a tau disease; and an increase in the relative amount of oligomeric huntingtin, which indicates the presence and activity of Huntington's disease or the progression to Huntington's disease. Thus, an abnormal spectrum of such oligomers indicates a process of neurodegeneration.

[0032] As used herein, the term "biomarker profile" refers to data indicating a quantitative measurement of each of one or more than one neurodegenerative protein forms, including one or more oligomeric forms and optionally one or more monomeric forms. This includes oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally hyperphosphorylated tau and optionally monomeric tau; and the amount of species of oligomeric huntingtin and optionally monomeric huntingtin. For example, a biomarker profile may include (I) at least one oligomeric form; (II) more than one oligomeric form; (III) at least one oligomeric form and at least one monomeric form; (IV) more than one oligomeric form and at least one monomeric form; (V) at least one oligomeric form and more than one monomeric form; and (VI) more than one oligomeric form and more than one monomeric form.

[0033] Protein form can refer to a separate protein species or a collection of species. For example, a 6-mer of alpha-synuclein is a form of alpha-synuclein. In addition, a collection of 6-mers to 18-mers of alpha-synuclein can be collectively a form of alpha-synuclein.

[0034] The biomarker spectrum can include more than one form of the protein. In one embodiment, the biomarker spectrum can include quantitative measurements of each of more than one oligomeric form and monomeric form of the neurodegenerative protein. Thus, for example, the biomarker spectrum can include quantitative measurements of each of dimers, trimers, tetramers, 5-mers, 6-mers, 7-mers, 8-mers, 9-mers, 10-mers, 11-mers, 12-mers, 13-mers, 14-mers, 15-mers, 16-mers, 19-mers.

[0035] Quantitative measurements can be absolute measurements, normalized measurements (e.g., measurements relative to a reference), and relative measurements. For example, in one embodiment, the biomarker profile includes the relative amounts of oligomeric forms of a neurodegenerative protein relative to monomeric forms of the neurodegenerative protein.

[0036] The term "biomarker profile" may also be used to refer to specific patterns in a profile that the model infers are associated with diagnosis, staging, progression, rate, prognosis, drug responsiveness, and risk of developing a neurodegenerative condition. Thus, a "synuclein biomarker profile" refers to a profile comprising oligomeric alpha-synuclein and optionally monomeric alpha-synuclein, the term "amyloid biomarker profile" refers to a profile comprising oligomeric beta-amyloid and optionally monomeric beta-amyloid, the term "tau biomarker profile" refers to a profile comprising oligomeric tau and optionally monomeric tau, and the term "huntingtin biomarker profile" refers to a profile comprising oligomeric huntingtin and optionally monomeric huntingtin.

[0037] As used herein, the term "monomeric protein / polypeptide" refers to a single, non-aggregated protein or polypeptide molecule, including any species thereof, such as phosphorylated species. As used herein, the term "oligomeric protein / polypeptide" refers to a single oligomeric species or an aggregate comprising more than one oligomeric species (including phosphorylated species). It should be understood that the measurement of the oligomeric form of an albumen as used herein can refer to the measurement of all oligomeric forms (total oligomeric forms) or specific oligomeric forms. Specific oligomeric forms can include, for example, forms within a specific size range or physical conditions, such as, for example, soluble fibrils.

[0038] Abnormal spectra (e.g., the relative amount of an increase in oligomeric forms relative to monomeric forms or an increase or decrease in certain oligomeric forms relative to other oligomeric forms) indicate pathological activity, and therefore indicate the time of future clinical onset and the rate of subsequent clinical progression. In addition, the recovery of the biomarker spectrum to normal (e.g., the decrease in the relative amount of oligomeric forms relative to monomeric forms) reflects the efficacy of candidate neuroprotective interventions. Therefore, the biomarker spectra described herein can be used to determine the efficacy of drug candidates for their neuroprotective effects.

[0039] Therefore, biomarker profiles are used not only as a diagnosis of an existing pathological state, but also as a sentinel for pathology prior to clinical onset, such as when a subject is presymptomatic or preclinical, e.g., with signs or symptoms that are insufficient for diagnosis of the disease. This is important because the relative success of neuroprotective treatments often appears to be associated with their earliest possible administration. In addition, it is believed that these biomarker profiles indicate the staging or extent of neurodegenerative conditions. Therefore, determining a biomarker profile (e.g., the relative amounts of oligomeric and monomeric forms of a selected protein) can be used to determine the effectiveness of a treatment, e.g., in a clinical trial, and can be used for therapeutic interventions that are believed to be effective for treating neurodegeneration in an individual, including, e.g., synuclein diseases, amyloid diseases, tau diseases, or Huntington's disease.

[0040] In each of these conditions, it is believed that the oligomeric / aggregated forms of the polypeptides described herein are toxic to neurons, because biomarker profiles comprising oligomeric and optionally monomeric forms of these polypeptides play a role in models for inferring pathological activity. In particular, increased relative amounts of oligomeric forms compared to monomeric forms are indicative of pathology. Measurement of these biomarkers can be used to track the response of a subject to existing or developing therapies, as well as to predict the development of a disease or the state or progression of an existing disease.

[0041] A. Synuclein disease

[0042] 1. Situation

[0043] As used herein, the terms "synucleinopathy" and "synucleinopathy condition" refer to a condition characterized by an abnormal spectrum of oligomeric α-synuclein, which is an abnormal aggregated form of α-synuclein. In certain embodiments, synucleinopathy manifests as clinically apparent synuclein diseases, such as, for example, PD, Lewy body dementia, multiple system atrophy, and some forms of Alzheimer's disease, as well as other rare neurodegenerative disorders such as various axonal dystrophies. Signs and optionally symptoms sufficient for clinical diagnosis of a synuclein disease are those symptoms that are generally sufficient for a person skilled in the art to make such a clinical diagnosis of such a condition.

[0044] Parkinson's disease ("PD") is a progressive disorder of the central nervous system (CNS) with a prevalence of 1% to 2% in the adult population over 60 years of age. PD is characterized by motor symptoms, including tremor, rigidity, postural instability, and slow voluntary movements. The etiology of the idiopathic form of the disease, which accounts for more than 90% of total PD cases, remains elusive, but is now believed to involve both environmental and genetic factors. Motor symptoms are significantly associated with the progressive degeneration of dopamine-producing neurons in the substantia nigra. Recently, PD has become one of a recognized group of multisystem disorders that primarily affect the basal ganglia (e.g., PD) or the cerebral cortex (e.g., Lewy body dementia) or the basal ganglia, brainstem, and spinal cord (e.g., multiple system atrophy), and they are all associated by the presence of intracellular deposits (Lewy bodies) composed primarily of a brain protein called α-synuclein. Therefore, these disorders, along with Hallevorden-Spatz syndrome, neuronal axonal dystrophies, and traumatic brain injury, are often referred to as "synucleinopathies."

[0045] Signs and symptoms of PD can include, for example, tremor at rest, rigidity, bradykinesia, postural instability, and a jerky, parkinsonian gait. One sign of PD is that these motor dysfunctions respond positively to carbidopa-levodopa.

[0046] The clinically recognized Parkinson's disease stages include the following: Stage 1 - mild; Stage 2 - moderate; Stage 3 - intermediate; Stage 4 - severe; Stage 5 - late.

[0047] At present, the diagnosis of PD relies mainly on the results of physical examination, which are usually quantified by using a modified Hoehn and Yahr rating scale (Hoehn and Yahr, 1967, Neurology, 17:5, 427-442) and the Unified Parkinson's Disease Rating Scale (UPDRS). The differential diagnosis of PD relative to other forms of Parkinson's disease such as progressive supranuclear palsy (PSP) can prove difficult, and misdiagnosis may therefore occur in up to 25% of patients. In fact, PD usually remains undetected for many years before an initial clinical diagnosis can be made. When this happens, the loss of dopamine neurons in the substantia nigra has exceeded 50% and may approach 70%. Blood tests for PD or any related synuclein diseases have not yet been validated. Although imaging studies using positron emission tomography (PET) or MRI have been used in the diagnosis of PD by providing information about the location and extent of neurodegenerative processes, they confer little or no information about the pathogenesis of the observed degeneration and do not guide the selection of specific synuclein-specific interventions.

[0048] Lewy body dementia (LBD) affects approximately 1.3 million people in the United States. Symptoms include, for example, dementia, cognitive fluctuations, parkinsonism, sleep disturbances, and hallucinations. It is the second most common form of dementia after Alzheimer's disease and usually develops after age 50. Like Parkinson's disease, LBD is characterized by abnormal deposition of alpha-synuclein in the brain.

[0049] Multiple system atrophy (MSA) is classified into two types, Parkinsonian and cerebellar. Parkinsonian is characterized by Parkinsonian symptoms such as PD. Cerebellar is characterized by impaired movement and coordination, dysarthria, visual disturbances and dysphagia, for example. MSA symptoms reflect cell loss and gliosis or astrocyte proliferation in damaged areas of the brain, especially in the substantia nigra, striatum, inferior olive nucleus and cerebellum. Abnormal alpha-synuclein deposition is characteristic.

[0050] The diagnostic error rate for PD and other synucleinopathies may be relatively high, especially during their initial staging, a situation that may become important with the introduction of effective disease-modifying therapies such as neuroprotective therapies.

[0051] 2. α-Synuclein

[0052] Alpha-synuclein is a protein found in the human brain. Human alpha-synuclein consists of 140 amino acids and is encoded by the SNCA gene (also known as PARK1). (Alpha-synuclein: Gene ID: 6622; Homo sapiens; Cytogenetic location: 4q22.1.)

[0053] As used herein, the term "α-synuclein" includes normal (unmodified) species and modified species. α-synuclein can exist in monomeric form or aggregated form. α-synuclein monomers can be abnormally aggregated into oligomers, and oligomeric α-synuclein can be aggregated into fibrils. Fibrils can further aggregate to form intracellular deposits known as Lewy bodies. It is believed that monomeric α-synuclein and its multiple oligomers exist in equilibrium. Alpha-synuclein processing in the brain can also produce other presumed abnormal species, such as α-synuclein phosphorylated at serine 129 ("p129 α-synuclein").

[0054] Alpha-synuclein is expressed in large quantities in the human central nervous system (CNS) and is expressed to a lesser extent in a variety of other organs. In the brain, alpha-synuclein is mainly found in neuronal endings, especially in the cerebral cortex, hippocampus, substantia nigra and cerebellum, where it helps to regulate neurotransmitter release. Under normal circumstances, this soluble monomeric protein tends to form a stable folded tetramer that resists aggregation. However, in some pathological conditions, for unknown reasons, alpha-synuclein abnormally β-folds, misfolds, oligomerizes and aggregates to eventually form protofibrils, which is a metabolic pathway that can produce highly cytotoxic intermediates.

[0055] As used herein, the term "monomeric alpha-synuclein" refers to a single, non-aggregated alpha-synuclein molecule, including any species thereof. As used herein, the term "oligomeric alpha-synuclein" refers to an aggregate comprising more than one alpha-synuclein molecule. This includes total oligomeric alpha-synuclein and forms or selected species thereof. Oligomeric alpha-synuclein includes forms with at least two monomer units up to the protofibril form. This includes oligomeric forms with, for example, between 2 and about 100 monomer units, for example, between 4 and 16 monomer units or at least 2 dozen, 3 dozen, 4 dozen or 5 dozen monomer units. As used herein, the term "relatively low-weight synuclein oligomer" refers to a synuclein oligomer comprising up to 30 monomer units (30-mers). Typically, relatively low-weight synuclein oligomers are soluble. In certain embodiments, α-synuclein refers to one or more than one form detected by a specific detection method. For example, these forms can be those detectable with antibodies raised against specific monomeric or oligomeric forms of α-synuclein.

[0056] The neurotoxic potential of the alpha-synuclein that abnormal processing is oligomerized form is now considered to promote the pathological conditions mentioned above, particularly the onset and subsequent progression of the symptoms of PD, Lewy body dementia, multiple system atrophy and several other disorders. These are generally defined as a group of neurodegenerative disorders, which are characterized in part by the intracellular accumulation of abnormal alpha-synuclein aggregates, some of which show toxicity and may promote the pathogenesis of the disorders mentioned above. It is still unknown how some oligomerized forms of alpha-synuclein may cause neurodegeneration, although the effects of such factors such as oxidative stress, mitochondrial damage and pore formation have been proposed. However, many people now believe that the process leading to alpha-synuclein oligomerization and aggregation may be extremely important for cell damage and destruction occurring in these disorders.

[0057] Some studies have shown that prefibrillar synuclein oligomers and protofibrils are particularly prone to confer neurotoxicity (Loov et al., “α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities”, M. Cell Mol Neurobiol. 2016 Apr;36(3):437-48. doi:10.1007 / s10571-015-0317-0). Other studies have suggested that lower oligomeric synuclein species may be the primary cause, and it is unclear which synuclein species, or which ensembles of species with different β-sheet arrangements, acting alone or synergistically through single or multiple pathological mechanisms, are most neurotoxic in PD or any related synucleinopathies (Wong et al., "α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies", Nat Med. 2017 Feb 7;23(2):1-13. doi:10.1038 / nm.4269).

[0058] A portion of intracellular synuclein, along with some of its metabolites, is packaged in exosome vesicles and released into the intracellular fluid in the brain, from where it enters the cerebrospinal fluid (CSF) and peripheral blood circulation. α-Synuclein is a protein found in the human brain. Human α-synuclein consists of 140 amino acids and is encoded by the SNCA gene (also known as PARK1). (α-Synuclein: Gene ID: 6622; Homo sapiens; Cytogenetic location: 4q22.1.)

[0059] B. Amyloid disease

[0060] 1. Situation

[0061] As used herein, the term "amyloid disease" refers to a condition characterized by the accumulation of amyloid polymers in the brain. Amyloid diseases include, but are not limited to, Alzheimer's disease and certain other neurodegenerative disorders such as late PD. Alzheimer's disease is the most common form of dementia. It is characterized by the accumulation of amyloid plaques consisting of aggregated forms of β-amyloid protein, and neurofibrillary tangles at the anatomical level. Symptoms are characterized by progressive memory loss, cognitive impairment, and neurobehavioral changes. Alzheimer's is progressive, and there is currently no known method to prevent or reverse the disease.

[0062] 2. Amyloid beta

[0063] Amyloid β (also known as amyloid-β, Aβ, A-β and β-amyloid) is a peptide fragment of the amyloid precursor protein. Amyloid β typically has between 36 and 43 amino acids. Amyloid β aggregates to form soluble oligomers that can exist in several forms. It is believed that misfolded oligomers of amyloid β can cause other amyloid β molecules to assume misfolded oligomeric forms. A-β 1-42 It has the following amino acid sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA [SEQ ID NO: 1].

[0064] In Alzheimer's disease, amyloid-β and tau proteins become oligomerized and accumulate in brain tissue where they have been shown to cause neuronal damage and loss; indeed, some assert that such soluble aggregate intermediates or oligomers are key species that mediate toxicity and underlie the seeding and spread of the disease (The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. Cline EN, Bicca MA, Viola KL, Klein WL. J Alzheimers Dis. 2018; 64(s1): S567-S610; "Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases," Choi ML, Gandhi S. FEBS J. 2018 Jun 20). Amyloid β oligomers are critical for the onset and progression of AD and represent a popular drug target that may be the most direct biomarker. Tau protein can also become abnormally hyperphosphorylated.

[0065] Current methods for quantifying monomeric and oligomeric forms of A-β include enzyme-linked immunosorbent assay (ELISA), methods for single oligomer detection, and others, which are mainly biosensor-based methods ("Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid", Schuster J, Funke SA. J Alzheimers Dis. 2016 May 7; 53(1): 53-67).

[0066] Surface-based fluorescence intensity distribution analysis (sFIDA) is characterized by both highly specific and sensitive oligomer quantification and complete insensitivity to monomers (“Advancements of the sFIDA method for oligomer-based diagnostics of neurodegenerative diseases”, Kulawik A. et al., FEBS Lett. 2018 Feb;592(4):516-534).

[0067] C. tauopathy

[0068] 1. Situation

[0069] As used herein, the term "tauopathy" refers to a condition characterized by accumulation and aggregation of tau protein associated with neurodegeneration. Tauopathies include, but are not limited to, Alzheimer's disease ("AD"), progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia with Parkinson's disease associated with chromosome 17, and Pick's disease.

[0070] AD is also characterized by a second pathological feature, neurofibrillary tangles (NFTs). NFTs are anatomically associated with neuronal loss, linking the process of NFT formation to neuronal damage and brain dysfunction. The main component of NFTs is a hyperphosphorylated form of tau, a microtubule-associated protein. During the formation of NFTs, tau forms a variety of different aggregates, including tau oligomers. There is increasing evidence that the formation of tau oligomers precedes the appearance of neurofibrillary tangles and contributes significantly to neuronal loss. (J Alzheimers Dis. 2013; 37(3): 565-8 "Tauopathies and tauoligomers", Takashima A.)

[0071] Non-fibrillar, soluble polymers appear to be more toxic than neurofibrillary tangles composed of filamentous tau.

[0072] In frontotemporal dementia, full-length TAR DNA binding protein ("TDP-43") forms toxic amyloid oligomers that accumulate in the frontal brain region. TDP-43 protein diseases (which also include amyotrophic lateral sclerosis (ALS)) are characterized by inclusion bodies formed by polyubiquitinated and hyperphosphorylated full-length and truncated TDP-43. Recombinant full-length human TDP-43 forms structurally stable globular oligomers that share common epitopes with anti-amyloid oligomer-specific antibodies. TDP-43 oligomers have been found to be neurotoxic both in vitro and in vivo. (Nat Commun. 2014 Sep 12; 5: 4824. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients). Determination of the presence and abundance of TDP-43 oligomers can be accomplished using specific antibodies against TDP-43 amyloid oligomers, termed TDP-O, in different subtypes of FTLD-TDP ("Detection of TDP-43 oligomers in frontotemporal lobar degeneration-TDP", Kao PF, Ann Neurol. 2015 Aug;78(2):211-21).

[0073] 2. tau

[0074] Tau is a phosphoprotein with 79 potential serine (Ser) and threonine (Thr) phosphorylation sites on the longest tau isoform. Tau exists in six isoforms, which are distinguished by the number of their binding domains. Three isoforms have three binding domains, and other three isoforms have four binding domains. Isoforms are produced by the alternative splicing in exon 2, exon 3 and exon 10 of tau gene. Tau is encoded by the MAPT gene, which has 11 exons. Haplogroup H1 shows a probability correlation with the increase of some dementias such as Alzheimer's disease.

[0075] Various tau oligomer species, including those ranging from 6-mers to 18-mers, have been implicated in neurotoxic processes associated with tauopathy brain disorders and measured by Western blotting and other techniques including single molecule fluorescence. (See, e.g., Kjaergaard M., et al., “Oligomer Diversity during the Aggregation of the Repeat Region of Tau” ACS Chem Neurosci. 2018 Jul 17; Ghag G, et al., “Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior”, Protein Sci. 2018 Aug 20. doi:10.1002 / pro.3499; and Comerota MM, et al., “Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies”, Mol Neurobiol. 2018 Aug 17).

[0076] Methods for measuring oligomeric tau species include immunoassays. Tau can be separated by common expression followed by chromatography such as affinity chromatography, size exclusion chromatography, and anion exchange chromatography. This form can be used to immunize animals to produce antibodies. Aggregation of tau can be induced using arachidonic acid. Oligomers can be purified by centrifugation on a sucrose step gradient. Oligomeric forms of tau can also be used to immunize animals and produce antibodies. Sandwich enzyme-linked immunosorbent assays using tau oligomer-specific PDC1 antibodies can be used to detect oligomeric tau. Tau oligomer complex 1 (PDC1) antibodies specifically recognize oligomeric tau species in tris-insoluble, sarkosyl-soluble fractions. (Shirafuji N., et al., "Homocysteine ​​Increases Tau Phosphorylation, Truncation and Oligomerization", Int J Mol Sci. 2018 Mar 17; 19(3)). (See, e.g., Methods Cell Biol. 2017; 141: 45-64. doi: 10.1016 / bs.mcb.2017.06.005. Epub 2017 Jul 14. Production of recombinant tau oligomers in vitro. Combs Bl, Tiernan CT1, Hamel Cl, Kanaan NM).

[0077] D. Huntington's disease

[0078] 1. Huntington’s disease

[0079] Huntington's disease is a genetic disease caused by an autosomal dominant mutation in the huntingtin gene. The mutation is characterized by a repeat of the CAG triplet. Huntington's disease is characterized by progressive neurodegeneration. Symptoms include movement disorders, such as involuntary movements, impaired gait, and difficulty swallowing and speaking. Huntington's disease is also characterized by progressive cognitive decline.

[0080] 2. Huntingtin

[0081] Huntingtin protein is encoded by the huntingtin gene, also known as HTT or HD. Normal huntingtin protein has about 3144 amino acids. The protein is usually about 300KdA.

[0082] In Huntington's disease (HD), cleavage of the full-length mutant huntingtin protein (mHtt) into smaller, soluble, aggregation-prone mHtt fragments represents a key process in the pathophysiology of this disorder. Indeed, aggregation and cytotoxicity of mutant proteins containing an expanded number of polyglutamine (polyQ) repeats are hallmarks of several diseases in addition to HD. Intracellularly, mutant huntingtin (mHtt) and other polyglutamine-expanded mutant proteins exist as monomers, soluble oligomers, and insoluble inclusion bodies. (J Huntingtons Dis. 2012; 1(1): 119-32. Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules. Sontag EM, et al. Brain Sci. 2014 Mar 3; 4(1): 91-122. Monomeric, oligomeric and polymeric proteins in Huntington disease and other diseases of polyglutamine expansion. Hoffner G. et al.). In certain embodiments, the oligomer is 2 nm-10 nm in height with an aspect ratio (longest distance spanned to shortest distance spanned) of less than 2.5, indicating a globular structure.

[0083] II. Detection and Measurement of Monomers and Oligomers

[0084] A. Biological samples

[0085] As used herein, the term "sample" refers to a composition that includes an analyte. A sample can be a raw sample, in which the analyte is mixed with other materials (e.g., source materials) in its native form; a fractionated sample, in which the analyte is at least partially enriched; or a purified sample, in which the analyte is at least substantially pure. As used herein, the term "biological sample" refers to a sample containing biological material, including, for example, polypeptides, polynucleotides, polysaccharides, lipids, and higher levels of these materials such as exosomes, cells, tissues, or organs.

[0086] Neurodegenerative proteins, such as oligomeric and monomeric forms of alpha-synuclein, amyloid beta, tau, and huntingtin can be detected in exosomes from a body fluid sample of a subject. More specifically, isolates of CNS-derived exosomes are a preferred subset of exosomes for detecting and analyzing synuclein pathological conditions. In particular, proteins from the internal compartment of exosomes are useful.

[0087] Exosomes can be isolated from a variety of biological samples from a subject. In certain embodiments, the biological sample is a body fluid. The body fluid source of the exosomes includes, for example, blood (e.g., whole blood or a fraction thereof such as serum or plasma, e.g., peripheral venous blood), cerebrospinal fluid, saliva, milk, and urine or a fraction thereof.

[0088] Due to the safety, acceptability and convenience of routine venipuncture in medical institutions, the use of venous blood as a source of exosomes is a preferred sample for diagnostic tests for both adults and children. Because the target analyte can be present in small amounts in the blood, a large number of samples can be collected. For example, the sample can have at least 5ml, at least 10ml, at least 20ml of blood. Serum can be prepared by allowing whole blood to coagulate and removing the clot by, for example, centrifugation. Plasma can be prepared by, for example, treating whole blood with an anticoagulant such as EDTA and removing blood cells by, for example, centrifugation. The blood sample can be provided by collecting the sample from the subject or by receiving the sample from a person who has collected blood from the subject. The blood sample will usually be refrigerated, for example, on ice or frozen at -80°C.

[0089] B. Methods for Determining the Amounts of Oligomeric and Monomeric Polypeptides

[0090] Monomeric and oligomeric forms of the protein can be detected by any method known in the art, including but not limited to immunoassays (e.g., ELISA), mass spectrometry, size exclusion chromatography, Western blot, and fluorescence-based methods (e.g., fluorescence spectroscopy or FRET) and proximity ligation assays.

[0091] 1. Alpha-synuclein

[0092] The amount of monomeric α-synuclein and oligomeric α-synuclein can be determined separately. Alternatively, the total α-synuclein in the sample can be measured with either monomeric α-synuclein or oligomeric α-synuclein, and the amount of the other species can be determined based on the difference.

[0093] Monomeric α-synuclein, oligomeric α-synuclein and total α-synuclein can be detected by, for example, immunoassay (e.g., ELISA or Western blot), mass spectrometry or size exclusion chromatography. Antibodies against α-synuclein are commercially available from, for example, Abcam (Cambridge, MA), ThermoFisher (Waltham, MA) and Santa Cruz Biotechnology (Dallas, TX).

[0094] The following references describe methods for measuring total α-synuclein content. Mollenhauer et al. (Movement Disorders, 32:8 p. 1117 (2017) describe methods for measuring total α-synuclein from body fluids. Loov et al. (Cell Mol. Neurobiol., 36:437-448 (2016)) describe the use of antibodies to separate L1CAM-positive exosomes from plasma. Abd-Elhadi et al. (Anal Bioanal Chem. (2016) November; 408 (27): 7669-72016) describe methods for determining total α-synuclein levels in human blood cells, CSF, and saliva by lipid-ELISA.

[0095] Total α-synuclein can be detected in ELISA using, for example, anti-human α-synuclein monoclonal antibody 211 (Santa Cruz Biotechnology, USA) for capture and anti-human α-synuclein polyclonal antibody FL-140 (Santa Cruz Biotechnology, USA) for detection by horseradish peroxidase (HRP)-linked chemiluminescent assay. Such a method avoids the detection of monomeric α-synuclein, but cannot distinguish between different polymeric forms.

[0096] Monomeric and oligomeric forms of alpha-synuclein can be detected, for example, by immunoassays using antibodies specific for these forms. See, for example, Williams et al. ("Oligomeric alpha-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases", Eur J Neurosci. (2016) January; 43 (1): 3-16) and Majbour et al. ("Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease", Molecular Neurodegeneration (2016) 11: 7). El-Agnaf O. et al. (FASEB J. 2016; 20: 419–425) describe the detection of oligomeric forms of alpha-synuclein in human plasma as potential biomarkers for PD.

[0097] Antibodies to α-synuclein monomers and oligomers can be produced by immunizing animals with α-synuclein monomers or oligomers. (See, e.g., U.S. Publication 2016 / 0199522 (Lannfelt et al.), 2012 / 0191652 (El-Agnaf)). α-synuclein oligomers can be prepared by the method of El Agnaf (US2014 / 0241987), wherein a freshly prepared α-synuclein solution is mixed with dopamine at a molar ratio of 1:7 (α-synuclein: dopamine) and incubated at 37°C. Antibodies against different oligomeric forms of α-synuclein are also described in Emadi et al. (“Isolation of a Human Single Chain Antibody Fragment Against Oligomeric α-Synuclein that Inhibits Aggregation and Prevents α-Synuclein-induced Toxicity”, J Mol Biol. 2007; 368: 1132–1144. [PubMed: 17391701]) (dimers and tetramers) and Emadi et al. (“Detecting Morphologically Distinct Oligomeric Forms of α-Synuclein”, J Biol Chem. 2009; 284: 11048–11058. [PubMed: 19141614]) (trimers and hexamers). Protofibril binding antibodies are described, for example, in US 2013 / 0309251 (Nordstrom et al.).

[0098] Monomeric α-synuclein can be distinguished from polymeric α-synuclein by immunoassay using antibodies that are uniquely recognized by oligomeric forms of synuclein. Another method involves detection of mass differences, such as using mass spectrometry. Fluorescence methods can be used. (See, e.g., Sangeeta Nath, et al., "Early Aggregation Steps in α-Synuclein as Measured by FCS and FRET: Evidence for a ContagiousConformational Change" Biophys J. 2010 April 7; 98 (7): 1302–1311, doi: 10.1016 / j.bpj.2009.12.4290; and Laura Tosatto et al., "Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants", Scientific Reports 5, December 2015). Another approach involves measuring total alpha synuclein, followed by proteinase K digestion of non-pathological alpha synuclein and detection of remaining alpha synuclein. Another approach involves an alpha synuclein proximity ligation assay. Protein ligation assay probes are generated from antibodies raised against the protein of interest, one antibody raised against each of the proteins involved in the putative interaction, which are conjugated to short oligonucleotides. If the probe binds to the interacting protein, the oligonucleotides are close enough to trigger an amplification reaction, which can be detected by the tagged oligonucleotide and observed as a punctate signal, where each dot represents an interaction. (Roberts RF et al., “Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain.Brain,” 2015;138:1642–1657.doi:10.1093 / brain / awv040, and Nora Bengoa-Vergniory et al., “Alpha-synuclein oligomers: a new hope,” Acta Neuropathol. 2017;134(6):819–838).

[0099] The relative amounts of oligomeric forms of α-synuclein relative to monomers can be expressed as a ratio.

[0100] The quantity or amount may be expressed as a signal output from an assay or as an absolute amount after conversion, for example from a standard curve, for example in mass / volume.

[0101] The α-synuclein species in the sample can be further separated into different classes. For example, the oligomer species can be separated into lower oligomers such as 2 to 24 monomeric units, higher oligomers such as 24 to 100 monomeric units or protofibrils, etc.

[0102] 2. Amyloid beta

[0103] Oligomers and monomers can be distinguished using an enzyme-linked immunosorbent assay (ELISA). This assay is similar to a sandwich ELISA. Aβ monomers contain one epitope, while oligomers contain more than one of these epitopes. Therefore, if epitope-overlapping antibodies to the above unique epitopes are used for capture and detection antibodies, binding to the specific and unique epitope will result in competition between the two antibodies. In other words, a monomer will be occupied by either the capture antibody or the detection antibody, but not by both. ("Oligomeric forms of amyloid-βprotein in plasma as a potential blood-based biomarker for Alzheimer's disease", Wang MJ et al. Alzheimers Res Ther. 2017 Dec 15;9(1):98. "Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty", RuanQ et al., Mol Med Rep. 2016 Oct;14(4):3184-98. "Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid," Schuster J, Funke SA. J Alzheimers Dis. 2016 May 7;53(1):53-67).

[0104] Oligomeric forms of amyloid β detected include, for example, 4-24-mers of amyloid β.

[0105] 3. tau

[0106] Tau oligomers in biological fluids such as CSF can be measured by ELISA and Western blot analysis using anti-tau oligomer antibodies. (Sengupta U, et al., "Tau oligomers in cerebrospinal fluid in Alzheimer's disease", Ann Clin Transl Neurol. 2017 Apr; 4(4): 226–235).

[0107] The oligomers of tau detected include, for example, low molecular weight oligomers, such as no more than 20-mers, such as 3-18-mers. The presence of soluble oligomers in cerebrospinal fluid can be detected using monoclonal anti-oligomer antibodies using Western blot and sandwich enzyme-linked immunosorbent assay (sELISA). David, MA et al., "Detection of protein aggregates inbrain and cerebrospinal fluid derived from multiple sclerosis patients", Front Neurol. 2014 Dec 2; 5:251. Oligomeric forms of tau include hyperphosphorylated forms of oligomeric tau.

[0108] 4. Huntingtin

[0109] Recent quantitative studies have used TR-FRET-based immunoassays. A combined size exclusion chromatography (SEC) and time-resolved fluorescence resonance energy transfer (TR-FRET) detection method allows the resolution and definition of native soluble mhtt species and insoluble aggregate formation and aggregation in the brain. "Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging", Marcellin D. et al., PLoS One. 2012; 7(9): e44457.

[0110] A variety of published techniques have been used to detect oligomeric huntingtin species, including, for example, agarose gel electrophoresis (AGE) analysis (under native or mildly denaturing, 0.1% SDS conditions or Blue-Native PAGE under native conditions), which provides a plurality of immunoreactive oligomers; anti-huntingtin antibodies discriminately recognize specific huntingtin oligomers.

[0111] A one-step TR-FRET-based immunoassay has been developed to quantify soluble and aggregated mHtt in cells and tissue homogenates (TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in Huntington's disease. Baldo B, et al., Chem Biol. 2012 Feb 24;19(2):264-75).

[0112] Determination based on time-resolved Forster energy transfer (TR-FRET) represents a high-throughput, homogeneous, sensitive immunoassay widely used to quantify proteins of interest. TR-FRET is extremely sensitive to small distances and can therefore provide conformational information based on the relative position of the epitope present on the target protein as detected by the selective antibody recognition. We have previously reported a TR-FRET assay based on the use of antibodies specific for different amino-terminal HTT epitopes to quantify HTT proteins (Fodale, V. et al., "Polyglutamine-and temperature-dependent conformationalrigidity in mutant huntingtin revealed by immunoassays and circular dichroismspectroscopy", PLoS One. December 2, 2014; 9(12): e112262.doi:10.1371 / journal.pone.0112262.eCollection 2014).

[0113] C. Isolation of Exosomes

[0114] Exosomes are extracellular vesicles that are believed to be released from cells after the fusion of an intermediate endocytic compartment, a multivesicular body (MVB), with the plasma membrane. The vesicles released in this process are called exosomes. Exosomes are believed to facilitate the diffusion of toxic synuclein species between CNS neurons and into CSF ​​and other body fluids. Exosomes are typically in the range of about 20 nm to about 100 nm.

[0115] Many methods for isolating exosomes are known in the art. These include, for example, immunoaffinity capture methods, size-based separation methods, differential ultracentrifugation, exosome precipitation, and microfluidic-based separation techniques. (Loov et al., "α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities", M. Cell Mol Neurobiol. April 2016; 36(3): 437-48. doi: 10.1007 / s10571-015-0317-0).

[0116] The amount of exosomes in a sample can be determined by any of a number of methods. These include, for example, (a) immunoaffinity capture (IAC), (b) asymmetric flow field-flow fractionation (AF4), (c) nanoparticle tracking analysis (NTA), (d) dynamic light scattering (DLS), and (e) surface plasmon resonance (SPR)

[66] . Reprinted with permission. Immunoaffinity capture (IAC) is an exosome capture technique that uses an indirect separation method via immunoaffinity. IAC quantifies exosomes by analyzing color, fluorescence, or electrochemical signals. Asymmetric flow field-flow fractionation (AF4) uses field-flow fractionation and diffusion to separate and quantify molecules. Nanoparticle tracking analysis (NTA) separates and quantifies particles based on their size. NTA uses the rate of Brownian motion to analyze particles. The technique also uses light scattering techniques to track the concentration and size of exosomes. Dynamic light scattering (DLS) determines particle size by light scattered by particles that exhibit Brownian motion. Surface plasmon resonance (SPR) is an immunoaffinity-based assay that captures exosomes using receptors on the surface of an SPR sensor. Binding changes the optical signal of the receptors, and their resonance can then be quantified by a light source. In another approach, exosomes can be examined by electron microscopy, for example, by visualization in a Zeiss LSM 200 transmission electron microscope at 120 kV.

[0117] 1. Immunoaffinity capture

[0118] Immunoaffinity capture methods use antibodies attached to an extraction moiety to bind exosomes and separate them from other substances in the sample. The solid support can be, for example, magnetically attractable microparticles. Latex immunobeads can be used.

[0119] Qiagen describes its exoEasy Maxi Kit as using membrane affinity spin columns to efficiently isolate exosomes and other extracellular vesicles from serum, plasma, cell culture supernatants, and other biofluids.

[0120] 2. Size-based methods

[0121] Size-based separation methods include, for example, size exclusion chromatography and ultrafiltration. In size exclusion chromatography, a porous stationary phase is used to separate exosomes based on size. In ultrafiltration, a porous membrane filter is used to separate exosomes based on their size or weight.

[0122] 3. Differential Ultracentrifugation

[0123] Differential ultracentrifugation involves a series of centrifugation cycles of varying centrifugal forces and durations to separate exosomes based on differences in density and size between the exosomes and other components in the sample. The centrifugal force can be, for example, from ~100,000×g to 120,000×g. Protease inhibitors can be used to prevent protein degradation. A previous cleanup step can be used to remove other large material from the sample.

[0124] 4. Density Gradient Ultracentrifugation

[0125] Density gradient ultracentrifugation uses gradient media such as sucrose, Nycodenz (iohexol) and iodixanol to sort exosomes. Exosomes are separated into a layer where the density of the gradient medium is equal to the density of the exosomes via ultracentrifugation.

[0126] 5. Polymer-based methods

[0127] Exosomes can be separated from a solution of biological material by changing their solubility or dispersibility. For example, the addition of a polymer, such as polyethylene glycol (PEG), for example polyethylene glycol (PEG) having a molecular weight of 8000 Da, can be used to precipitate exosomes from a solution.

[0128] 6. Microfluidics-based methods

[0129] Microfluidics-based methods can be used to separate exosomes. These include, for example, acoustic methods, electrophoretic methods, and electromagnetic methods. For example, acoustic nanofilters use ultrasonic standing waves to separate exosomes in a sample based on their size and density.

[0130] 7. Other methods

[0131] Other methods for isolating CNS-derived exosomes are described, for example, in Kanninnen, KM et al., “Exosomes as new diagnostic tools in CNS diseases”, Biochimica et Biophysica Acta, 1862 (2016) 403-410.

[0132] 8. Enrichment of CNS-derived exosomes

[0133] CNS-derived exosomes are exosomes produced in the central nervous system, as distinguished from the peripheral nervous system.

[0134] Immunoaffinity methods can be used to separate CNS-derived exosomes using brain-specific biomarkers (e.g., neural and glial markers), one such marker being L1CAM. Another marker is KCAM. Other relatively brain-specific proteins can also perform this function. CNS-derived exosomes are characterized by brain-related protein markers, including, for example, KCAM, L1CAM, and NCAM. (See, e.g., US 2017 / 0014450, US 2017 / 0102397, US 9,958,460). CNS-derived exosomes can be separated using affinity capture methods. Such methods include, for example, paramagnetic beads attached to antibodies against specific markers such as L1 CAM. (See, e.g., Shi et al., "Plasma exosomal α-alpha-synuclein is likely CNS-derived and increased in Parkinson's disease", Acta Neuropathol. 2014 November; 128(5): 639–650).

[0135] D.Exosome contents

[0136] Many proteins associated with the pathogenesis of human neurodegenerative diseases, such as alpha synuclein, are produced outside the CNS and in the brain and can become attached to the outer surface of exosomes that cross the blood-brain barrier and enter the peripheral circulation. Therefore, in certain embodiments of the methods disclosed herein, the exosome fraction is treated to remove molecules bound to the surface of the exosomes. This can be accomplished, for example, by a rigorous washing procedure, such as washing with phosphate buffered saline (PBS). After such treatment, the contents of the exosomes can be processed for assay.

[0137] The scrubbed exosomes can then be lysed and their inner contents released for analysis.

[0138] E. Detection of protein forms from exosomes

[0139] 1. Egg white

[0140] a) α-synuclein oligomers

[0141] Alpha synuclein oligomers and optionally other protein species are determined from the scrubbed exosome contents.

[0142] b) Copolymers of α-synuclein

[0143] In addition to its ability to self-assemble into a variety of oligomer species, α-synuclein also interacts with other proteins, including tau and amyloid β. α-synuclein and tau interact to form copolymers. The aggregation of amyloid β1-42 in vitro is affected by the interaction of α-synuclein and amyloid β. Amyloid β1-42 and amyloid β1-40 bind to α-synuclein in solution. Therefore, detecting a molecule according to the methods disclosed herein can include detecting a copolymer of α-synuclein with any of tau and amyloid β.

[0144] 2. Total amount

[0145] Quantitative measurements of protein forms in a sample can be measured. Quantitative measurements can be absolute measurements, normalized measurements (e.g., relative to a reference measurement), and relative measurements. For example, in one embodiment, a biomarker profile includes the relative amount of oligomeric forms of a neurodegenerative protein relative to a monomeric form of the neurodegenerative protein. In another embodiment, quantitative measurements can be expressed as a pattern of protein forms.

[0146] The total amount of various protein forms can be measured from the exosome content fraction. This includes total oligomeric α-synuclein. It can also include the total amount of monomeric α-synuclein or the total amount of phosphorylated α-synuclein. In addition, the total amount of one or more forms of tau and / or one or more forms of amyloid β can also be quantified. The form of tau includes monomeric tau, oligomeric tau and phosphorylated tau. The form of amyloid β includes A-β1-40, A-β1-42, oligomeric A-β and phosphorylated A-β. Any combination of these forms can be measured. This includes groups of forms, such as total α-synuclein, total tau or total A-β.

[0147] 3. Oligomeric α-synuclein species

[0148] Specific oligomeric forms of α-synuclein can be distinguished by using detection agents specific for the oligomeric species.

[0149] Alternatively, the oligomeric species in the mixture can be separated from each other and then detected. The oligomeric species in the mixture can be separated by several methods. In one method, the species are separated by electrophoresis. This includes gel electrophoresis. Electrophoresis methods include polyacrylamide gel electrophoresis ("PAGE") and agarose gel electrophoresis. In one method, native PAGE or blue native PAGE is used. Native PAGE Bis-Tris gels are obtained from, for example, Available. In a method known as "packed-capillary electrophoresis" or "pCE", arbitrarily wide pores are created by filling the capillaries with non-porous colloidal silica. Alternatively, the species can be separated by chromatography, such as size exclusion chromatography, liquid chromatography, or gas chromatography.

[0150] After separation, the specific oligomeric forms of alpha-synuclein can be distinguished. This can be done without the need for a binding agent that specifically binds to a specific oligomeric form, because they have been separated and are therefore distinguishable. Typically, a binding agent that is bound to an alpha-synuclein oligomer can be used to detect the form. Their position on the gel or the time of elution from the column can be used to indicate the specific form detected. For example, the migration of larger oligomers in a gel is usually slower than that of smaller oligomers.

[0151] a) Western blotting

[0152] In one embodiment, the method of detection is protein blotting. In protein blotting, the protein in the mixture is separated by electrophoresis. The separated protein is usually blotted onto a solid support, such as a nitrocellulose filter, by electroblotting. The blotted protein can be detected by direct binding with a binding agent for alpha-synuclein oligomers, or by indirect binding in which, for example, the blot is contacted with a primary antibody for a label of alpha-synuclein oligomers, and the primary antibody of the label is allowed to bind to the oligomer. Usually, the blot is washed to remove unbound antibodies. Then, the oligomeric form is detected using a labeled antibody for the primary antibody (commonly referred to as a secondary antibody) or a label attached to the primary antibody.

[0153] Labels can include, for example, gold nanoparticles, latex beads, fluorescent molecules, luminescent proteins, and enzymes that produce a detectable product from a substrate. Tags can include, for example, biotin.

[0154] In addition to detecting oligomeric forms of α-synuclein, copolymers of oligomeric α-synuclein and various forms of tau or amyloid β can also be detected. These forms can be detected using binding agents that bind to the desired form of tau or amyloid β. Copolymers can migrate at different speeds than oligomers of α-synuclein having the same number of monomeric α-synuclein subunits, and therefore can be individually detectable.

[0155] Multiple different oligomeric forms of α-synuclein can be detected, for example, simultaneously. These measurements can be combined to form a biomarker profile.

[0156] III. Determining the diagnosis, staging, progression, prognosis, and risk of developing neurodegenerative conditions

[0157] Biomarker profiles comprising the amounts of oligomeric and optionally monomeric forms of neurodegenerative protein biomarkers in biological samples (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally hyperphosphorylated tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species) and changes in the profiles over time indicate the presence, severity, and direction of a neurodegenerative condition of a neurodegenerative type. In particular, abnormal ratios of the protein biomarkers disclosed herein, such as elevated amounts, indicate a process of neurodegeneration. This process, if unchecked, can lead to overt symptoms of synuclein pathological conditions. Thus, provided herein are methods of determining the diagnosis, staging, progression, rate, prognosis, drug responsiveness, and risk of developing a neurodegenerative condition in a subject (e.g., in a symptomatic individual or an asymptomatic individual) that is characterized by abnormal amounts of aggregated proteins, such as α-synuclein, amyloid β, tau, or huntingtin (each referred to herein as a "neuropathic state," e.g., a "synucleinopathy state," "amyloidopathy state," "tauopathy state," "huntingtinopathy state").

[0158] As used herein, the term "diagnosis" refers to the classification of an individual as having or not having a particular pathogenic condition, including, for example, the stage of the condition.

[0159] As used herein, the term "clinically similar but etiologically different" refers to conditions that share clinical signs and / or symptoms but are caused by different biological causes.

[0160] As used herein, the term "staging" refers to the relative severity of a condition, such as suspected disease, early, intermediate, or advanced stage. Staging can be used to group patients based on etiology, pathophysiology, severity, etc.

[0161] As used herein, the term "progression" refers to the change or lack of change in the stage or severity of a condition over time. This includes an increase, decrease, or stagnation in the severity of a condition. In certain embodiments, the rate of progression, i.e., the change over time, is measured.

[0162] As used herein, the term "prognosis" refers to the process of prediction, such as the likelihood of a condition progressing. For example, a prognosis may include a prediction that the severity of a condition may increase, decrease, or remain unchanged at a certain future time point. In the context of the present disclosure, a prognosis may refer to an individual (1) who will develop a neurodegenerative condition, (2) who will progress from one stage to another more advanced stage of the condition, (3) who will exhibit a reduction in the severity of the condition, (4) who will exhibit functional decline at a certain rate, (5) who will survive with the condition for a certain period of time (e.g., survival rate), or (6) who will have a likelihood of recurrence of the condition. The condition may be a synucleinopathy condition (e.g., PD, Lewy body dementia, multiple system atrophy, or some related synucleinopathy), an amyloidopathy condition (e.g., Alzheimer's disease), a tauopathy condition (e.g., Alzheimer's disease), and Huntington's disease. These terms are not meant to be absolute, as will be understood by any technician in the field of medical diagnosis.

[0163] As used herein, the term "risk of development" refers to the probability that an asymptomatic or preclinical individual will develop a clear diagnosis of the disease. Determining the probability includes both exact probability and relative probability such as "more likely", "very likely", "unlikely" or percentage probability, for example "90%". The risk can be compared with the general population or with a population matched with the subject based on any one of age, sex, genetic risk and environmental risk factors. In such a case, the subject can be determined to be at an increased or reduced risk compared to other members of the population.

[0164] Typically, an increased relative amount of oligomeric neurodegenerative proteins relative to monomeric neurodegenerative proteins, such as alpha-synuclein, beta amyloid, tau, and huntingtin, is associated with a neurodegenerative process, the presence of a disease, a more advanced stage of the disease, progression to a more severe stage, a worse prognosis, an increased risk of developing the disease, or ineffectiveness of an experimental therapeutic intervention. In certain embodiments, it is preferred to measure alpha-synuclein from CNS-derived exosomes in peripheral blood. For example, an increase in the relative amount of the oligomeric form relative to the monomeric form by at least 10%, at least 20%, at least 50%, at least 100%, at least 250%, at least 500%, or at least 1000% as compared to normal indicates an abnormal condition, such as the presence of a disease.

[0165] IV. Modeling the Species of Neurodegenerative Proteins to Infer Diagnosis, Staging, Progression, Prognosis, and Risk of Development of Neurodegenerative Conditions

[0166] Determining the diagnosis, staging, progression, prognosis, and risk of a neurodegenerative condition is the process of classifying a subject into different categories or situations within different conditions or states, such as disease / health (diagnosis), phase I / II / III (staging), possible remission / possible progression (prognosis), or assigning scores within a range. Methods of using biomarker spectrum classification can include identifying spectra that are characteristic of multiple states, and associating spectra from subjects with categories or states. Identifying such spectra can include analyzing biomarker spectra from subjects belonging to different states, and discerning patterns or differences between spectra. Analysis can be accomplished by visual inspection of the spectra or by statistical analysis.

[0167] A. Statistical Analysis

[0168] Typically, analysis includes statistical analysis of a sufficiently large number of samples to provide statistically significant results. Any statistical method known in the art can be used for this purpose. Such methods or tools include, but are not limited to, correlation, Pearson correlation, Spearman correlation, chi-square, mean comparison (e.g., paired T test, independent T test, ANOVA), regression analysis (e.g., simple regression, multiple regression, linear regression, nonlinear regression, logistic regression, polynomial regression, stepwise regression, ridge regression, lasso regression, elastic network regression) or nonparametric analysis (e.g., Wilcoxon rank sum test, Wilcoxon signed rank test, sign test). Such tools are included in commercially available statistical packages such as MATLAB, JMP statistical software and SAS. Such methods produce models or classifiers, and people can use these models or classifiers to classify specific biomarker spectra into specific states.

[0169] Statistical analysis can be operator-implemented or performed through machine learning.

[0170] B. Machine Learning

[0171] In certain embodiments, statistical analysis is enhanced by using machine learning tools. Such tools use learning algorithms, in which one or more important variables (relevant variable or variables) are measured under different possible states, and the mode of distinguishing states is determined and used to classify test subjects. Therefore, any classification method of the present disclosure can be developed by comparing the measured values ​​of one or more variables in subjects belonging to a variety of conditions within a specific synuclein disease state. This includes, for example, determining the biomarker spectrum of the amount of one or more forms of oligomeric alpha-synuclein and optionally monomeric alpha-synuclein contained in subjects with different diagnoses or different stages at different times, to allow predictive diagnosis, staging, progression, prognosis, drug responsiveness or risk. Other variables may also be included, such as family history, lifestyle, exposure to chemicals, multiple phenotypic traits, etc.

[0172] 1. Training Dataset

[0173] A training data set is a data set that typically contains a vector of values ​​for each of more than one feature for each of more than one subject (more generally referred to as an object). One of the features can be a classification of the subject, for example, a diagnosis or a measure of degree on a scale. This can be used for supervised learning methods. Other features can be, for example, the amount of measurement of each of more than one different forms of neurodegenerative proteins. Different forms will include more than one different species, including, for example, one or more oligomeric forms and optionally one or more monomeric forms. Typically, features will include more than one different oligomeric forms and optionally one or more monomeric forms. Thus, for example, a vector for an individual subject can include a diagnosis of a neurodegenerative condition (e.g., diagnosed as having or not having Parkinson's disease) and a measurement of more than one form selected from monomeric alpha synuclein, dimeric alpha synuclein, trimeric alpha synuclein, tetrameric alpha synuclein...28-mer alpha synuclein, 29-mer alpha synuclein, and 30-mer alpha synuclein. In other embodiments, the form is a collection of species, such as relatively low molecular weight alpha-synuclein species. In certain embodiments, the training data set for generating a classifier includes data from at least 100, at least 200, or at least 400 different subjects. The ratio of subjects classified as suffering from the condition relative to subjects classified as not suffering from the condition can be at least 2: 1, at least 1: 1, or at least 1: 2. Alternatively, the preclassification of subjects suffering from the condition can include no more than 66%, no more than 50%, no more than 33%, or no more than 20% of the subjects.

[0174] 2. Learning Algorithms

[0175] A learning algorithm, also known as a machine learning algorithm, is a computer-implemented algorithm that automates analytical model building, such as for clustering, classification, or spectral recognition. A learning algorithm analyzes a training data set provided to the algorithm.

[0176] The learning algorithm outputs a model, also known as a classifier, classification algorithm, or diagnostic algorithm. The model receives test data as input and produces as output an inference or classification of the input data as belonging to one or another class, cluster group, or position on a scale, such as diagnosis, stage, prognosis, disease progression, responsiveness to a drug, etc.

[0177] A variety of machine learning algorithms can be used to infer the condition or state of an experimenter. A machine learning algorithm can be supervised or unsupervised. Learning algorithms include, for example, artificial neural networks (for example, back propagation networks), discriminant analysis (for example, Bayesian classifiers or Fischer analysis), support vector machines, decision trees (for example, recursive partitioning processes such as CART classification and regression trees), random forests, linear classifiers (for example, multiple linear regression (MLR), partial least squares (PLS) regression and principal component regression (PCR)), hierarchical clustering and cluster analysis. The learning algorithm will generate and can be used to make inferences, for example, models or classifiers for inferences about the disease state of an experimenter.

[0178] 3. Verification

[0179] The model can then be validated using a validation dataset. The validation dataset typically includes data on the same features as the training dataset. The model is executed on the training dataset and the number of true positives, true negatives, false positives, and false negatives is determined as a measure of the performance of the model.

[0180] The model can then be tested on a validation data set to determine its usefulness. Typically, a learning algorithm will generate more than one model. In certain embodiments, the model can be validated based on the fidelity of standard clinical measurements used to diagnose the condition under consideration. One or more of these can be selected based on their performance characteristics.

[0181] C. Computer

[0182] The classification of the condition of the subject based on any of the states described herein can be performed by a programmable digital computer. The computer may include a tangible memory that receives and optionally stores at least one or more oligomeric forms and optionally monomeric forms of protein biomarkers in the subject (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species) measured values; and a processor that processes the data by executing a code embodying a classification algorithm. The classification algorithm can be the result of a statistical analysis implemented by an operator or a statistical analysis implemented by machine learning.

[0183] The system includes a first computer as described that communicates with a communication network, the communication network being configured to transmit data to the computer and / or transmit the results of the test, such as the classification as described herein, to a remote computer. The communication network can utilize, for example, a high-speed transmission network, including but not limited to a digital subscriber line (DSL), a cable modem, optical fiber, wireless, satellite, and broadband over power lines (BPL). The system can also include a remote computer connected to the first computer via the communication network.

[0184] D. Model execution and making inferences

[0185] The selected model can be produced by statistical analysis or machine learning performed by an operator. In any case, the model can be used to make an inference (e.g., prediction) about a test subject. Biomarker spectra can be generated from a sample taken from a test subject, for example in the form of a test data set, for example, including a vector of values ​​of features used by the model. The test data set can include all the same features used in the training data set, or a subset of these features. Then, the model is applied to the test data set or executed on the test data set. It is a form of execution model to associate neurodegenerative protein spectra with conditions, disease states, prognosis, the risk of progress, the possibility of drug response, etc. Association can be performed by people or by machines. Selection can depend on the complexity of the association operation. This produces an inference, for example, the subject is classified as belonging to a category or a cluster group (such as diagnosis) or a position on a scale (such as the possibility of response to therapeutic intervention).

[0186] In certain embodiments, the classifier will include more than one oligomeric protein form of the neurodegenerative protein and typically but not necessarily one or more monomeric forms of the neurodegenerative protein. The classifier may or may not be a linear model, such as a linear model of the form AX+BY+CZ=N, where A, B, and C are measured quantities of forms X, Y, and Z. The classifier may require, for example, support vector machine analysis. For example, an inference model can perform pattern recognition, in which the biomarker spectrum is located on a scale between normal and abnormal, with a variety of spectra tending more toward normal or toward abnormal. Therefore, the classifier can indicate that the spectrum is normal or abnormal confidence level.

[0187] A classifier or model can generate a single diagnostic value (diagnostic number) used as a model from one or more than one form measured. Classifying a neuropathological state such as a synuclein disease state (e.g., diagnosis, staging, progression, prognosis, and risk) can include determining whether the diagnostic value is above or below a threshold value ("diagnostic level"). For example, a diagnostic value can be the relative amount of an oligomeric neurodegenerative protein (e.g., α-synuclein) relative to a monomeric neurodegenerative protein (e.g., α-synuclein) (including measuring a specific species or phosphorylated form of each protein). For example, the threshold can be determined based on a certain deviation from a diagnostic value higher than a normal individual, and the normal individual does not have any signs of a neurodegenerative condition such as a synuclein disease condition. A measure of the central tendency of the diagnostic value, such as a mean, median, or mode, can be determined in a statistically significant number of normal individuals and abnormal individuals. A cutoff value higher than the normal amount can be selected as a diagnostic level for a neurodegenerative condition such as a synuclein disease condition. The value can be, for example, a degree of deviation from a measure of central tendency, such as variance or standard deviation. In one embodiment, the measure of deviation is a Z score or the number of standard deviations from a normal mean. In certain embodiments, an amount of oligomeric alpha-synuclein to monomeric alpha-synuclein greater than 1.5:1, 2:1, 5:1, or 10:1 indicates the presence or increased risk of a neurodegenerative condition, such as a synucleinopathy condition.

[0188] Model can be selected to provide the sensitivity, specificity or positive predictive ability of the desired level. For example, the diagnostic level can provide at least any one of 80%, 90%, 95% or 98% sensitivity and / or at least any one of 80%, 90%, 95% or 98% specificity, and / or at least any one of 80%, 90%, 95% or 98% positive predictive value. The sensitivity of the test is the percentage of actual positives that the test is positive. The specificity of the test is the percentage of actual negatives that the test is negative. The positive predictive value of the test is the probability that a subject who tests positive is actually positive.

[0189] V. Development of therapeutic interventions to treat neurodegenerative conditions

[0190] In another aspect, provided herein are methods that enable practical development of therapeutic interventions for neurodegenerative conditions, such as synucleinopathy conditions, amyloidopathy conditions, tauopathy conditions, and Huntington's disease. The methods include, among other things, selecting subjects for clinical trials and determining the effectiveness of the therapeutic intervention in a group of subjects.

[0191] Methods comprising monitoring biomarker profiles of neurodegenerative proteins (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species) can be used to determine whether an experimental therapeutic intervention is effective in preventing clinical onset or inhibiting subsequent progression of a synucleinopathy, or whether a subject should enter a clinical trial to test the efficacy of a drug candidate to treat such a condition. Biomarker profiles of neurodegenerative proteins or changes in biomarker profiles (e.g., the relative amounts or rates of change in the relative amounts of oligomeric and monomeric forms of a protein biomarker (e.g., oligomeric α-synuclein and monomeric α-synuclein; oligomeric amyloid β and monomeric amyloid β; oligomeric tau and monomeric tau; and oligomeric huntingtin and monomeric huntingtin species)) enable direct determination of the effect of a treatment on a condition, including, for example, an underlying disease process.

[0192] A. Subject recruitment

[0193] Clinical trials include recruitment of subjects for testing the efficacy and safety of potential therapeutic interventions such as drugs. Typically, subjects are selected to have different conditions of status, for example, with or without the diagnosis of the disease or in different stages of the disease or different subtypes of the disease or different prognoses. Clinical trial subjects can be stratified into different groups to carry out the same or different treatments. The stratification can be based on any number of factors, including the stages of the disease. The stage of disease is to use diagnostic findings to produce a classification system for patient clustering based on factors such as etiology, pathophysiology and severity. It can be used as a basis for making clinically homogeneous patient clustering to assess the quality of care, the analysis of clinical outcomes, the utilization of resources and the efficacy of selectable treatment.

[0194] In one approach, potential clinical trial subjects are stratified based at least in part on the biomarker profiles of oligomeric and optionally monomeric forms of protein biomarkers (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species). Thus, for example, subjects with different biomarker profiles (e.g., higher and lower relative amounts) can be assigned to different groups.

[0195] The population of subjects in a clinical trial should be sufficient to show whether the drug produces a statistically significant difference in the results. Depending on the power level, the number of individuals in the trial can be at least 20, at least 100, or at least 500 subjects. Among these, there must be a significant number of individuals presenting a biomarker profile consistent with having a neurodegenerative condition (e.g., an increased level of a synuclein biomarker, i.e., the relative level of oligomeric α-synuclein to monomeric α-synuclein). For example, at least 20%, at least 35%, at least 50%, or at least 66% of the subjects may initially have such a biomarker profile (including, for example, oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally multiple species of monomeric huntingtin). In addition, a significant number of subjects will be divided between the category states. For example, at least 20%, at least 35%, at least 50%, at least 66%, or 100% of the subjects may initially have a diagnosis of a neurodegenerative condition (e.g., synucleinopathy conditions (e.g., PD), amyloidopathy conditions, tauopathy conditions, and Huntington's disease).

[0196] B. Drug Development

[0197] After the start of the clinical trial, the effectiveness of the therapeutic intervention on different stratified groups can be quickly determined as a function of the biomarker spectrum of the neurodegenerative protein (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species) changes. More specifically, changes in the biomarker spectrum of the oligomeric form and optionally monomeric form of the protein predict the clinical effectiveness of the therapeutic intervention. The method generally includes first testing an individual to determine a biomarker spectrum comprising an oligomeric form and optionally monomeric form of a protein biomarker (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species). After the measurement, a therapeutic intervention, such as an experimental drug, is administered to at least a subset of the subject. Typically, at least one subset of subjects is given a placebo or is not given treatment. In some cases, subjects are used as their own controls, first receiving a placebo, and then receiving the experimental intervention, or conversely, for comparison. In some cases, this can be combined with the administration of a recognized treatment form to complete. Colonies can be divided according to the administration, time, and rate of administration of the therapeutic intervention. When statistically significant improvement is observed in the test subjects, ethical considerations may require stopping the study. As used herein, "experimental drug" and "drug candidate" refer to an agent with a therapeutic effect or a therapeutic effect being tested. "Presumed neuroprotectant" refers to an agent with a neuroprotective effect or being tested as a neuroprotective effect.

[0198] After administration of the therapeutic intervention, the biomarker profile is again determined.

[0199] The therapeutic intervention may be the administration of a drug candidate. Using standard statistical methods, it can be determined whether the therapeutic intervention has a meaningful effect on the biomarker spectrum comprising oligomeric and optionally monomeric forms of protein biomarkers (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and species of oligomeric huntingtin and optionally monomeric huntingtin). Typically, statistically significant changes compared to the initial biomarker spectrum, especially shifts to a normal spectrum, indicate that the therapeutic intervention has a neuroprotective effect, and therefore will delay clinical onset, or slow or preferably reverse the progression of a neurodegenerative condition (e.g., a synuclein pathological condition, an amyloid pathological condition, a tau pathological condition, Huntington's disease).

[0200] Thus, for subjects for whom a biomarker profile comprising oligomeric and monomeric forms of a protein (e.g., oligomeric α-synuclein and optionally monomeric α-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species) (alternatively, oligomeric and total forms of a protein) can be measured include, for example: (1) for a neurodegenerative condition (e.g., a synucleinopathy condition, an amyloid The present invention relates to subjects who are asymptomatic (i.e., proteolytic protein diseases, tauopathy conditions, Huntington's disease); (2) subjects who have minimal neurodegenerative disease symptoms and no physical signs suggestive of a neurodegenerative condition (e.g., who may be diagnosed as "suspected" or "preclinical" for a neurodegenerative condition, particularly when certain genetic and / or environmental risk factors have been identified); and (3) subjects who have a diagnosis of a "possible" neurodegenerative condition and subjects who have been diagnosed ("definitely diagnosed") as having a neurodegenerative condition. These include, for example, (1) subjects who are asymptomatic for a synucleinopathy condition, (2) subjects who have minimal Parkinson's symptoms and no signs suggestive of a synucleinopathy condition (e.g., who may be diagnosed as "suspected" or "preclinical" for PD or some related synucleinopathies, especially when certain genetic and / or environmental risk factors have been identified); (3) subjects with a diagnosis of a "possible" synucleinopathy (e.g., PD) and subjects who are diagnosed ("definitely diagnosed") as having a synucleinopathy condition.

[0201] The subject is usually a human, but also includes non-human animals, such as non-human animals used as models of PD, such as rodents (e.g., mice and rats), cats, dogs, other domesticated quadrupeds (such as horses, sheep and pigs) and non-human primates (e.g., monkeys). Animal models include both genetic models and models based on the administration of neurotoxins. Neurotoxins used in such models include, for example, 6-hydroxydopamine (6-OHDA) and 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) administration, as well as paraquat and rotenone. Genetic models include SNCA (α-synuclein, PARK1 and 4), PRKN (parkin RBR E3 ubiquitin protein ligase, PARK2), PINK1 (PTEN-induced putative kinase 1, PARK6), DJ-1 (PARK7) and genetic mutations of LRRK2 (leucine-rich repeat kinase 2, PARK8).

[0202] Clinical trials for neurodegenerative conditions such as neuroprotective therapies for synuclein diseases require measurements that rapidly indicate the effectiveness of potential therapies. Otherwise, it would typically take many months to determine drug efficacy based on clinical observations. Biomarker profiles comprising oligomers and optionally monomers of neurodegenerative proteins provide such measurements, thus enabling actual assessment of the efficacy of disease-modifying drugs in subjects suffering from fatal brain disorders such as PD.

[0203] VI. Treatment Methods

[0204] Depending on the stage or category of the neurodegenerative condition (e.g., synuclein pathological condition, amyloid pathological condition, tau pathological condition, Huntington's disease) into which the subject is classified based on the biomarker profile as described herein, the subject may require therapeutic intervention. Provided herein are methods for treating a subject determined by the methods disclosed herein to present with a neurodegenerative condition (e.g., synuclein pathological condition, and amyloid pathological condition, tau pathological condition, Huntington's disease) with a therapeutic intervention that is effective in treating the condition. A therapeutic intervention that alters the amount of oligomeric forms of a protein biomarker versus monomeric forms of a protein biomarker (e.g., oligomeric α-synuclein and monomeric α-synuclein; oligomeric amyloid β and monomeric amyloid β; oligomeric tau and monomeric tau; and oligomeric huntingtin and monomeric huntingtin) and in particular a therapeutic intervention that reduces the amount of oligomeric forms of a protein biomarker versus monomeric forms of a protein biomarker (e.g., oligomeric α-synuclein and monomeric α-synuclein; oligomeric amyloid β and monomeric amyloid β; oligomeric tau and monomeric tau; and oligomeric huntingtin and monomeric huntingtin) reflects an effective treatment, e.g., a therapeutic intervention developed and clinically validated by the methods herein.

[0205] As used herein, the terms "therapeutic intervention", "therapy" and "treatment" refer to an intervention that produces a therapeutic effect (e.g., is "therapeutically effective"). Therapeutically effective interventions prevent diseases such as synuclein pathological conditions, slow the progression of the disease, delay the onset of symptoms of the disease, improve the condition of the disease (e.g., cause remission of the disease), improve the symptoms of the disease, or cure the disease. Therapeutic interventions can include, for example, the administration of treatment, the administration of a drug substance or biological substance or nutrient with a therapeutic purpose. The response to the therapeutic intervention can be complete or partial. In some aspects, the severity of the disease is reduced by at least 10% compared to, for example, an individual before administration or a control individual who has not undergone treatment. In some aspects, the severity of the disease is reduced by at least 25%, 50%, 75%, 80% or 90%, or in some cases, it is no longer detectable using standard diagnostic techniques. Recognizing that certain subgroups of subjects may not respond to therapy, a measure of therapeutic effectiveness can be the effectiveness of at least 90% of the subjects who have experienced intervention in at least 100 subjects.

[0206] As used herein, the term "effective" when modifying a therapeutic intervention ("effective treatment" or "effective for...") or an amount of a drug ("effective amount") refers to a treatment or amount that improves a disorder as described above. For example, for a given parameter, a therapeutically effective amount will show an increase or decrease in the parameter by at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy may also be expressed as an increase or decrease "-fold". For example, a therapeutically effective amount may be at least 1.2-fold, 1.5-fold, 2-fold, 5-fold or more effective than a control. Currently, clinical efficacy for the severity of motor symptoms in Parkinson's subjects can be measured using standardized scales such as the UPDRS and the Hoehn and Yahr scales; for psychiatric and cognitive symptoms, ADAS-cog or MMPI scales can be used. (It is recognized that the utility of such a scale does not necessarily depend on the type or nature of the underlying disease condition.)

[0207] Thus, according to some methods, a subject is first tested for a biomarker profile that includes oligomeric and / or monomeric forms of a neurodegenerative protein in a biological sample from the subject. Classification of the appropriate condition or category is determined based on the biomarker profile. Based on the classification, a decision can be made about the type, amount, route, and time of the best effective therapeutic intervention to be administered to the subject.

[0208] A. Synucleinopathy

[0209] In certain embodiments, therapeutic interventions for PD to improve symptoms (i.e., symptomatic or palliative treatments) include administration of a drug selected from the group consisting of a dopamine agonist (e.g., pramipexole (e.g., Mirapex), ropinirole (e.g., Requip), rotigotine (e.g., Neupro), apomorphine (e.g., Apokyn)), levodopa, carbidopa-levodopa (e.g., Rytary, Sinemet), a MAO-B inhibitor (e.g., selegiline), ne) (e.g., Eldepryl, Zelapar) or rasagiline (e.g., Azilect), a catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone (Comtan) or tolcapone (Tasmar)), an anticholinergic (e.g., benztropine (e.g., Cogentin or trihexyphenidyl)), amantadine, or a cholinesterase inhibitor (e.g., rivastigmine (Exelon)), or some similar agent or combination of agents.

[0210] In certain embodiments, a neuroprotective or disease-modifying therapeutic intervention for PD comprises administration of a putative disease-modifying drug as described in any of the following provisional patent applications, which are incorporated herein by reference in their entireties: Serial No. 62 / 477187, filed March 27, 2017; Serial No. 62 / 483,555, filed April 10, 2017; Serial No. 62 / 485,082, filed April 13, 2017; Serial No. 62 / 511,424, filed May 26, 2017; Serial No. 62 / 528,228, filed July 3, 2017; Serial No. 62 / 489,016, filed April 24, 2017; Serial No. 62 / 527,215, filed June 30, 2017.

[0211] B. Amyloid Disease Conditions

[0212] In certain embodiments, therapeutic intervention for amyloid pathological conditions to improve symptoms (i.e., symptomatic or palliative treatment) comprises administration of a drug such as (galatamine), (rivastigmine) and (donepezil).

[0213] C. Tauopathy

[0214] In certain embodiments, therapeutic intervention for ameliorating symptoms of a tauopathy condition (i.e., symptomatic or palliative treatment) comprises administration of a drug such as (Galantamine), (rivastigmine) and (donepezil) or drugs cited herein for the symptomatic treatment of PD.

[0215] D. Huntington's disease

[0216] In certain embodiments, therapeutic interventions for ameliorating symptoms of Huntington's disease (i.e., symptomatic or palliative treatments) include administration of drugs such as tetrabenazine ( (deutrabenazine), IONIS-HTT Rx , as well as various tranquilizers and benzodiazepines kind.

[0217] VII. Methods for Assessing Responsiveness to Therapeutic Interventions

[0218] In subjects suffering from neurodegenerative disorders (e.g., synuclein pathological conditions, amyloid pathological conditions, tau pathological conditions, Huntington's disease), the effectiveness of a therapeutic intervention or the responsiveness of a subject to a therapeutic intervention can be determined by evaluating the effect of the therapeutic intervention on the biomarker profile. This includes effectiveness in any neurodegenerative state, such as diagnosis, staging, progression, prognosis, and risk. Changes in the biomarker profile to a more normal profile indicate the effectiveness of the therapeutic intervention.

[0219] The use of biomarker profiles comprising oligomeric and optionally monomeric forms of protein biomarkers (e.g., oligomeric alpha-synuclein and optionally monomeric alpha-synuclein; oligomeric amyloid β and optionally monomeric amyloid β; oligomeric tau and optionally monomeric tau; and oligomeric huntingtin and optionally monomeric huntingtin species) confers advantages over conventional means (e.g., changes in symptomology, functional scales, or radiological scans) for judging the efficacy of treatment in such cases. Such conventional means of judging efficacy are not only insensitive, imprecise, and semi-quantitative, but also typically require a long time (e.g., several years) before becoming of sufficient magnitude to accurately measure. As a result, the number of potentially useful treatments tested is significantly reduced, and the cost of clinical trials and therefore the ultimate cost of useful drugs is significantly increased.

[0220] In certain embodiments, the biomarker profile of a protein biomarker species (e.g., alpha-synuclein, amyloid beta, tau, or huntingtin) is typically measured more than once before, during, and after administration of a therapeutic intervention, or more than once at more than one time point after a therapeutic intervention.

[0221] VIII. Kit

[0222] In another aspect, provided herein are kits for detecting oligomeric protein biomarkers and monomeric protein biomarkers (e.g., oligomeric α-synuclein and monomeric α-synuclein; oligomeric amyloid β and monomeric amyloid β; oligomeric tau and monomeric tau; and oligomeric huntingtin and monomeric huntingtin species), and interpreting the results thus obtained. The kit may include a container containing reagents for isolating exosomes from body fluids, reagents for preferentially isolating CNS-derived exosomes from all exosomes, a first reagent sufficient to detect oligomeric forms of a protein biomarker (e.g., α-synuclein, amyloid β, tau, or huntingtin) and a second reagent sufficient to detect monomeric forms of a protein biomarker (e.g., α-synuclein, amyloid β, tau, or huntingtin), or reagents for detecting total protein biomarker species (e.g., α-synuclein, amyloid β, tau, or huntingtin).

[0223] For example, a kit for detecting and staging synucleinopathy disease states in biological samples may include reagents, buffers, enzymes, antibodies, and other compositions specifically for this purpose. The kit may also typically include instructions for use and software for data analysis and interpretation. The kit may also include samples used as standard standards. Each solution or composition may be contained in a vial or bottle, and all vials are tightly stored in a box for commercial sale.

[0224] Exemplary embodiments

[0225] Exemplary embodiments of the present invention include, but are not limited to, the following:

[0226] 1. A method, comprising:

[0227] a) enriching brain-derived exosomes from each biological sample in a collection of biological samples, wherein:

[0228] (i) The collection of biological samples is from subjects in a cohort of subjects, wherein the cohort includes subjects comprising:

[0229] (1) more than one subject diagnosed with a neurodegenerative condition, each at more than one different disease stage, wherein each of the diagnosed subjects has received a putative neuroprotective agent, and / or

[0230] (2) More than one healthy control subject,

[0231] wherein the biological sample is collected prior to administration of the putative neuroprotectant and again one or more times during administration of the putative neuroprotectant, and optionally after administration of the putative neuroprotectant;

[0232] b) isolating protein contents from the internal compartment of exosomes to generate biomarker samples;

[0233] c) measuring the amount of each of one or more than one neurodegenerative protein forms in the biomarker sample to create a data set, wherein the neurodegenerative protein forms include one or more oligomeric forms and optionally one or more monomeric forms; and

[0234] d) Perform statistical analysis on the data set to:

[0235] (i) comparing the amount of each of the neurodegenerative protein forms in individual subjects over time to determine a diagnostic algorithm that predicts the rate of disease progression or the degree of response to a putative neuroprotective agent; or

[0236] (ii) comparing differences in the amounts of each of the neurodegenerative protein forms between different subjects to determine a diagnostic algorithm that (1) makes an etiological diagnosis, (2) separates clinically similar but etiologically distinct subgroups of neurodegenerative disorders, or (3) predicts whether or to what extent a subject is likely to respond to a putative neuroprotective agent.

[0237] 2. The method according to any one of embodiment 1 or the above embodiments, further comprising, before enrichment:

[0238] I) providing a population of subjects, wherein the population includes subjects comprising: (i) more than one subject diagnosed with a neurodegenerative condition at each of more than one different disease stage, and / or (ii) more than one healthy control subject;

[0239] II) administering a putative neuroprotective agent to each of the diagnosed subjects;

[0240] III) collecting a biological sample from each of the subjects in the cohort before administration of the putative neuroprotectant and once or more times during administration of the putative neuroprotectant and optionally after administration of the putative neuroprotectant.

[0241] 3. The method according to any one of embodiment 1 or the above embodiments, wherein the neurodegenerative protein form measured is selected from:

[0242] (I) at least one oligomeric form;

[0243] (II) more than one oligomeric form;

[0244] (III) at least one oligomeric form and at least one monomeric form;

[0245] (IV) more than one oligomeric form and at least one monomeric form;

[0246] (V) at least one oligomeric form and more than one monomeric form; and

[0247] (VI) More than one oligomeric form and more than one monomeric form.

[0248] 4. The method according to any one of embodiment 1 or the above embodiments, wherein the diagnostic algorithm uses one or more forms selected from the following:

[0249] (I) at least one oligomeric form;

[0250] (II) more than one oligomeric form;

[0251] (III) at least one oligomeric form and at least one monomeric form (e.g., relative amounts);

[0252] (IV) more than one oligomeric form and at least one monomeric form;

[0253] (V) at least one oligomeric form and more than one monomeric form; and

[0254] (VI) More than one oligomeric form and more than one monomeric form.

[0255] 5. The method of embodiment 1 or any one of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of the neurodegenerative protein.

[0256] 6. The method according to any one of embodiments 1 or above, further comprising:

[0257] h) Validating one or more of the diagnostic algorithms against standard clinical measurements.

[0258] 7. A method according to any one of embodiment 1 or the above embodiments, wherein the statistical analysis includes: correlation, Pearson correlation, Spearman correlation, chi-square, mean comparison (e.g., paired T test, independent T test, ANOVA), regression analysis (e.g., simple regression, multiple regression, linear regression, nonlinear regression, logistic regression, polynomial regression, stepwise regression, ridge regression, lasso regression, elastic net regression) or non-parametric analysis (e.g., Wilcoxon rank sum test, Wilcoxon signed rank test, sign test).

[0259] 8. The method according to embodiment 1 or any one of the above embodiments, wherein the statistical analysis is performed by a computer.

[0260] 9. The method of any one of embodiment 8 or the above embodiments, wherein the statistical analysis comprises machine learning.

[0261] 10. The method according to embodiment 1 or any one of the above embodiments, wherein the subject is a human.

[0262] 11. The method of embodiment 1 or any one of the above embodiments, wherein the neurodegenerative condition is a synucleinopathic disorder.

[0263] 12. The method of embodiment 11 or any one of the above embodiments, wherein the synucleinopathy disorder is Parkinson's disease.

[0264] 13. The method of embodiment 11 or any one of the above embodiments, wherein the synucleinopathy disorder is dementia with Lewy bodies.

[0265] 14. The method of embodiment 12 or any one of the above embodiments, wherein the neurodegenerative protein is α-synuclein, and wherein the oligomeric form comprises one or more relatively low molecular weight synuclein oligomers.

[0266] 15. The method of any one of embodiment 12 or the above embodiments, wherein the neurodegenerative protein is α-synuclein, and wherein the oligomeric synuclein forms include oligomeric forms within a size range of about 6-mer to 18-mer.

[0267] 16. The method according to embodiment 12 or any one of the above embodiments, wherein standard clinical measurements are selected from UPDRS scores, CGI scores, and radiological findings.

[0268] 17. The method of embodiment 1 or any one of the above embodiments, wherein the neurodegenerative condition is an amyloid disease, a tau disease, or Huntington's disease.

[0269] 18. The method of embodiment 1 or any one of the above embodiments, wherein the biological sample comprises a venous blood sample.

[0270] 19. The method according to embodiment 1 or any one of the above embodiments, wherein different disease stages include one or more of suspected, early, intermediate and clinically advanced stages.

[0271] 20. The method according to embodiment 1 or any one of the above embodiments, wherein the time during or after administration is selected from 1 month, 2 months, 3 months or more months after treatment.

[0272] 21. The method of embodiment 1 or any one of the above embodiments, wherein enrichment comprises using one or more brain-specific protein markers.

[0273] 22. The method according to embodiment 21 or any one of the above embodiments, wherein at least one of the brain-specific markers comprises K1cam.

[0274] 23. The method according to embodiment 1 or any one of the above embodiments, wherein separation comprises washing the exosomes in each enriched sample to remove surface membrane-bound proteins.

[0275] 24. The method according to embodiment 23 or any one of the above embodiments, wherein the exosomes are washed with PBS.

[0276] 25. The method according to embodiment 1 or any one of the above embodiments, wherein the form of the neurodegenerative protein is measured by gel electrophoresis, Western blotting or fluorescence technology.

[0277] 26. A method comprising:

[0278] a) enriching brain-derived exosomes from a biological sample of a subject;

[0279] b) isolating protein contents from the internal compartment of exosomes to generate biomarker samples;

[0280] c) measuring the amount of each of one or more than one neurodegenerative protein forms in the biomarker sample to create a neurodegenerative protein profile, wherein the neurodegenerative protein forms include one or more oligomeric forms and optionally one or more monomeric forms; and

[0281] d) correlating the neurodegenerative protein profile to one of the following: (1) make an etiological diagnosis, (2) assign a subject to one of more than one clinically similar but etiologically distinct neurodegenerative disorder subgroups, or (3) predict whether or to what extent a subject is likely to respond to a putative neuroprotective agent.

[0282] 27. The method of embodiment 26 or any one of the above embodiments, wherein the association comprises executing the diagnostic algorithm of embodiment 1 on the neurodegenerative protein profile.

[0283] 28. The method according to embodiment 26 or any one of the above embodiments, wherein the diagnostic algorithm uses a neurodegenerative protein form selected from the group consisting of:

[0284] (I) at least one oligomeric form;

[0285] (II) more than one oligomeric form;

[0286] (III) at least one oligomeric form and at least one monomeric form;

[0287] (IV) more than one oligomeric form and at least one monomeric form;

[0288] (V) at least one oligomeric form and more than one monomeric form (e.g., the relative amounts of the oligomeric forms to the monomeric forms); and

[0289] (VI) More than one oligomeric form and more than one monomeric form.

[0290] 29. The method of embodiment 26 or any one of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of the neurodegenerative protein.

[0291] 30. A method according to embodiment 26, comprising collecting more than one biological sample from a subject over a period of time, optionally wherein the subject receives a putative or known neuroprotectant during the period of time, wherein the diagnostic algorithm predicts the rate of disease progression or the extent of response to the putative neuroprotectant.

[0292] 31. The method of embodiment 26 or any one of the above embodiments, wherein the diagnostic algorithm uses the relative amount of oligomeric forms relative to monomeric forms of the neurodegenerative protein.

[0293] 32. The method of embodiment 26 or any one of the above embodiments, wherein the diagnostic algorithm uses the pattern of one or more than one oligomeric forms of the neurodegenerative protein.

[0294] 33. A method comprising:

[0295] a) providing, for each of more than one subject, a dataset comprising values ​​indicative of: (1) the status of a neurodegenerative condition, and (2) a quantitative measure of the amount of each of one or more than one neurodegenerative protein forms in a biological sample enriched for CNS-derived microsomal particles, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0296] b) Statistical analysis of the dataset to develop a model for inferring the status of the neurodegenerative condition in an individual.

[0297] 34. The method according to any one of embodiment 33 or the above embodiments, wherein the quantitative measurement of one or more than one neurodegenerative protein form is selected from:

[0298] (I) at least one oligomeric form;

[0299] (II) more than one oligomeric form;

[0300] (III) at least one oligomeric form and at least one monomeric form;

[0301] (IV) more than one oligomeric form and at least one monomeric form;

[0302] (V) at least one oligomeric form and more than one monomeric form (e.g., the relative amounts of the oligomeric forms relative to the monomeric forms); and

[0303] (VI) More than one oligomeric form and more than one monomeric form.

[0304] 35. The method of embodiment 33 or any one of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of the neurodegenerative protein.

[0305] 36. The method of embodiment 33 or any one of the above embodiments, wherein the statistical analysis is performed by a computer.

[0306] 37. The method of embodiment 33 or any one of the above embodiments, wherein the statistical analysis is not performed by a computer.

[0307] 38. A method according to any one of embodiment 33 or the above embodiments, wherein the statistical analysis includes: correlation, Pearson correlation, Spearman correlation, chi-square, mean comparison (e.g., paired T test, independent T test, ANOVA), regression analysis (e.g., simple regression, multiple regression, linear regression, nonlinear regression, logistic regression, polynomial regression, stepwise regression, ridge regression, lasso regression, elastic net regression) or non-parametric analysis (e.g., Wilcoxon rank sum test, Wilcoxon signed rank test, sign test).

[0308] 39. A method according to embodiment 36 or any of the above embodiments, wherein the statistical analysis includes training a machine learning algorithm on the data set.

[0309] 40. A method according to any one of embodiment 39 or the above embodiments, wherein the machine learning algorithm is selected from: artificial neural networks (e.g., back-propagation networks), decision trees (e.g., recursive partitioning procedures, CART), random forests, discriminant analysis (e.g., Bayesian classifiers or Fischer analysis), linear classifiers (e.g., multivariate linear regression (MLR), partial least squares (PLS) regression, principal component regression (PCR)), mixed or random effects models, non-parametric classifiers (e.g., k-nearest neighbors), support vector machines, and ensemble methods (e.g., bagging, boosting).

[0310] 41. The method of embodiment 33 or any one of the above embodiments, wherein the status is selected from the diagnosis, staging, prognosis or progression of a neurodegenerative condition.

[0311] 42. A method according to any one of embodiment 33 or above, wherein the state is measured as a categorical variable (e.g., a binary state or one of more than one categorical state).

[0312] 43. A method according to embodiment 42 or any of the above embodiments, wherein the categories include diagnoses consistent with having a neurodegenerative condition (e.g., positive or diagnosed as having a neurodegenerative condition) and diagnoses inconsistent with having a neurodegenerative condition (e.g., negative or diagnosed as not having a neurodegenerative condition).

[0313] 44. The method of embodiment 42 or any one of the above embodiments, wherein the categories comprise different stages of the neurodegenerative condition.

[0314] 45. The method of embodiment 33 or any one of the above embodiments, wherein the state is measured as a continuous variable (e.g., on a scale).

[0315] 46. ​​The method of embodiment 41 or any one of the above embodiments, wherein the continuous variable is the range of the extent of the neurodegenerative condition.

[0316] 47. The method of any one of embodiment 33 or the above embodiments, wherein the subject is an animal, such as a fish, a bird, an amphibian, a reptile, or a mammal, such as a rodent, a primate, or a human.

[0317] 48. The method of any one of embodiment 33 or the above embodiments, wherein the more than one subject is at least any one of 25, 50, 100, 200, 400, or 800.

[0318] 49. A method according to embodiment 33 or any one of the above embodiments, wherein for each subject, the sample for which the quantitative measurement is determined is collected at a first time point and the status of the neurodegenerative condition is determined at a second later time point.

[0319] 50. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative protein is selected from α-synuclein, tau, amyloid β, and huntingtin.

[0320] 51. The method of any one of embodiment 33 or the above embodiments, wherein the biological sample comprises blood or a blood fraction (eg, plasma or serum).

[0321] 52. The method of embodiment 33 or any one of the above embodiments, wherein at least one oligomeric form comprises a phosphorylated form.

[0322] 53. A method according to any one of embodiment 33 or the above embodiments, wherein the neurodegenerative protein is α-synuclein and the data set includes quantitative measurements of oligomers ranging from 4-mers to 16-mers, individually or collectively, or including oligomers of p129 α-synuclein.

[0323] 54. A method according to any of embodiment 33 or the above embodiments, wherein the neurodegenerative protein is a soluble oligomeric form of amyloid β, and the data set includes quantitative measurements of oligomers in the approximate size range of 8-mers to 24-mers, either individually or collectively.

[0324] 55. The method of any one of embodiment 33 or the above embodiments, wherein the neurodegenerative protein is tau and the data set includes quantitative measurements of oligomers in the approximate range of 3-mers to 15-mers, either individually or collectively.

[0325] 56. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative protein is tau and the oligomeric form is a hyperphosphorylated form of tau.

[0326] 57. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative protein is huntingtin protein.

[0327] 58. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative condition is a synucleinopathy selected from Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, or a related disorder.

[0328] 59. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative condition is an amyloid disease, such as Alzheimer's disease.

[0329] 60. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative condition is a tauopathy, such as Alzheimer's disease.

[0330] 61. The method of embodiment 33 or any one of the above embodiments, wherein the neurodegenerative condition is Huntington's disease.

[0331] 62. A method of inferring the risk of development, diagnosis, staging, prognosis or progression of a neurodegenerative condition characterized by a neurodegenerative protein, wherein the method comprises:

[0332] a) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0333] b) executing a model, such as a model according to embodiment 33, on the dataset to infer the risk of development, diagnosis, staging, prognosis or progression of a neurodegenerative condition.

[0334] 63. The method according to any one of embodiment 62 or the above embodiments, wherein the neurodegenerative protein form for which the quantitative measurement is determined is selected from:

[0335] (I) at least one oligomeric form;

[0336] (II) more than one oligomeric form;

[0337] (III) at least one oligomeric form and at least one monomeric form;

[0338] (IV) more than one oligomeric form and at least one monomeric form;

[0339] (V) at least one oligomeric form and more than one monomeric form; and

[0340] (VI) More than one oligomeric form and more than one monomeric form.

[0341] 64. The method of embodiment 62 or any of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of a neurodegenerative protein.

[0342] 65. The method of embodiment 62 or any one of the above embodiments, wherein the model comprises comparing the relative amounts of oligomeric forms relative to monomeric forms of the neurodegenerative protein with the relative amounts in a statistically significant number of control individuals.

[0343] 66. A method according to embodiment 62 or any one of the above embodiments, wherein the model includes detecting patterns of relative amounts of more than one oligomeric form from which the model is inferred.

[0344] 67. The method of embodiment 62 or any one of the above embodiments, wherein the subject is asymptomatic or preclinical for the neurodegenerative condition.

[0345] 68. The method of embodiment 62 or any one of the above embodiments, wherein the subject sees a healthcare provider such as a physician during a routine office visit or as part of the physician's general medical practice.

[0346] 69. The method of embodiment 62 or any one of the above embodiments, wherein the model is executed by a computer.

[0347] 70. The method of any one of embodiment 62 or the above embodiments, wherein the model is not executed by a computer.

[0348] 71. A method for determining the effectiveness of a therapeutic intervention in treating a neurodegenerative condition characterized by a neurodegenerative protein, wherein the method comprises:

[0349] (a) in each subject in a population comprising more than one subject, inferring the initial state of the neurodegenerative condition by:

[0350] (1) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0351] (2) using a model, such as a model according to Embodiment 33, to infer the initial state;

[0352] (b) following the conclusion, administering a therapeutic intervention to the subject;

[0353] (c) after the administration, in each individual subject in the population, inferring the subsequent status of the neurodegenerative condition by:

[0354] (1) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0355] (2) using the model to infer subsequent states; and

[0356] (d) based on the initial extrapolation and the subsequent extrapolation in the population, determining that the therapeutic intervention is effective if the subsequent extrapolation shows a statistically significant change toward a normal state compared to the initial extrapolation, or determining that the therapeutic intervention is not effective if the subsequent extrapolation does not show a statistically significant change toward a normal state compared to the initial extrapolation.

[0357] 72. The method according to any one of embodiment 71 or the above embodiments, wherein the neurodegenerative protein form for which the quantitative measurement is determined is selected from:

[0358] (I) at least one oligomeric form;

[0359] (II) more than one oligomeric form;

[0360] (III) at least one oligomeric form and at least one monomeric form;

[0361] (IV) more than one oligomeric form and at least one monomeric form;

[0362] (V) at least one oligomeric form and more than one monomeric form; and

[0363] (VI) More than one oligomeric form and more than one monomeric form.

[0364] 73. The method of embodiment 71 or any one of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of a neurodegenerative protein.

[0365] 74. The method of embodiment 71 or any one of the above embodiments, wherein the therapeutic intervention comprises administering a drug or a combination of drugs.

[0366] 75. The method of any one of embodiment 71 or the above embodiments, wherein the population comprises at least 20, at least 50, at least 100 or at least 200 subjects, wherein at least 20%, at least 35%, at least 50% or at least 75% of the subjects initially have an elevated relative amount of the oligomeric form of the protein relative to the monomeric form of the protein.

[0367] 76. The method of any one of embodiment 71 or the above embodiments, wherein at least 20%, at least 25%, at least 30%, or at least 35%, at least 50%, at least 66%, at least 80% or 100% of the subjects initially have a diagnosis of a neurodegenerative condition.

[0368] 77. The method of embodiment 71 or any one of the above embodiments, wherein the model uses the relative amounts of oligomeric forms relative to monomeric forms of the neurodegenerative protein.

[0369] 78. The method of embodiment 71 or any one of the above embodiments, wherein the model uses a pattern of one or more than one oligomeric forms of the neurodegenerative protein.

[0370] 79. The method of any one of embodiment 71 or the above embodiments, wherein the inference is performed by a computer.

[0371] 80. The method of any one of embodiment 71 or the above embodiments, wherein the inference is not performed by a computer.

[0372] 81. A method for admitting a subject to a clinical trial for a therapeutic intervention for treating or preventing a neurodegenerative condition, the method comprising:

[0373] a) determining that the subject is abnormal with respect to a neurodegenerative condition characterized by a neurodegenerative protein by:

[0374] i) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0375] ii) performing a model, such as a model according to embodiment 33, on the profile to infer that the subject is abnormal with respect to a neurodegenerative condition; and

[0376] c) recruiting subjects in clinical trials for potential therapeutic interventions for said neurodegenerative conditions.

[0377] 82. The method according to embodiment 81 or any one of the above embodiments, wherein the neurodegenerative protein form for which the quantitative measurement is determined is selected from:

[0378] (I) at least one oligomeric form;

[0379] (II) more than one oligomeric form;

[0380] (III) at least one oligomeric form and at least one monomeric form;

[0381] (IV) more than one oligomeric form and at least one monomeric form;

[0382] (V) at least one oligomeric form and more than one monomeric form; and

[0383] (VI) More than one oligomeric form and more than one monomeric form.

[0384] 83. The method of embodiment 81 or any of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of a neurodegenerative protein.

[0385] 84. The method of embodiment 81 or any one of the above embodiments, wherein the model uses the relative amounts of oligomeric forms relative to monomeric forms of the neurodegenerative protein.

[0386] 85. The method of embodiment 81 or any one of the above embodiments, wherein the model uses a pattern of one or more than one oligomeric forms of the neurodegenerative protein.

[0387] 86. The method of embodiment 81 or any of the above embodiments, wherein the model is executed by a computer.

[0388] 87. The method of embodiment 81 or any of the above embodiments, wherein the model is not executed by a computer.

[0389] 88. A method of monitoring a subject's progress in response to a therapeutic intervention for a neurodegenerative condition, the method comprising:

[0390] (a) In the subject, the initial state of the neurodegenerative condition is inferred by:

[0391] (1) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0392] (2) executing a model, such as a model according to embodiment 33, to infer the initial state of the neurodegenerative condition;

[0393] (b) following the conclusion, administering a therapeutic intervention to the subject;

[0394] (c) after the administration, inferring the subsequent status of the neurodegenerative condition in the subject by:

[0395] (1) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0396] (2) executing a model, such as a model according to embodiment 33, to infer a subsequent state of a neurodegenerative condition;

[0397] (d) based on the initial state inference and the subsequent state inference, if the subsequent inference shows a change toward a normal state compared to the initial inference, then determining that the subject has a positive response to the therapeutic intervention, or if the subsequent inference does not show a change toward a normal state compared to the initial inference, then determining that the therapeutic intervention is not effective.

[0398] 89. The method according to embodiment 88 or any one of the above embodiments, wherein the neurodegenerative protein form for which the quantitative measurement is determined is selected from:

[0399] (I) at least one oligomeric form;

[0400] (II) more than one oligomeric form;

[0401] (III) at least one oligomeric form and at least one monomeric form;

[0402] (IV) more than one oligomeric form and at least one monomeric form;

[0403] (V) at least one oligomeric form and more than one monomeric form; and

[0404] (VI) More than one oligomeric form and more than one monomeric form.

[0405] 90. The method of embodiment 88 or any one of the above embodiments, wherein at least one of the oligomeric forms comprises a collection of species of the neurodegenerative protein.

[0406] 91. The method of embodiment 88 or any one of the above embodiments, wherein the model uses the relative amounts of oligomeric forms relative to monomeric forms of the neurodegenerative protein.

[0407] 92. The method of embodiment 88 or any one of the above embodiments, wherein the model uses a pattern of one or more than one oligomeric forms of the neurodegenerative protein.

[0408] 93. The method of embodiment 88 or any of the above embodiments, wherein the model is executed by a computer.

[0409] 94. The method of any one of embodiment 88 or the above embodiments, wherein the model is not executed by a computer.

[0410] 95. A method comprising:

[0411] (a) determining that the subject suffers from a neurodegenerative condition characterized by a neurodegenerative protein by the method according to embodiment 62, and

[0412] (b) administering to the subject a palliative or neuroprotective therapeutic intervention effective for treating the condition.

[0413] 96. The method of embodiment 95 or any one of the above embodiments, wherein the therapeutic intervention shifts the subject's biomarker profile toward normal, wherein the shift toward normal is indicative of neuroprotection.

[0414] 97. A method comprising administering to a subject having an abnormal biomarker profile as determined by the method described in embodiment 62 a palliative or neuroprotective therapeutic intervention effective to treat the condition.

[0415] 98. The method of embodiment 97 or any one of the above embodiments, wherein the subject is asymptomatic or preclinical for the neurodegenerative condition.

[0416] 99. A kit comprising a first reagent sufficient to detect an oligomeric form of a protein selected from the group consisting of α-synuclein, tau, amyloid β, and huntingtin and a second reagent sufficient to detect a monomeric form of a protein selected from the group consisting of α-synuclein, tau, amyloid β, and huntingtin.

[0417] 100. The kit of embodiment 99 or any one of the above embodiments, wherein the first reagent and the second reagent comprise antibodies.

[0418] 101. A method of inferring the risk of development, diagnosis, staging, prognosis or progression of a neurodegenerative condition characterized by a neurodegenerative protein, wherein the method comprises:

[0419] a) determining a neurodegenerative protein profile from a biological sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; and

[0420] b) Correlate the neurodegenerative protein profile with the risk of development, diagnosis, staging, prognosis or progression of a neurodegenerative condition.

[0421] 102. The method of embodiment 101 or any one of the above embodiments, wherein the neurodegenerative protein profile comprises a quantitative measurement selected from the group consisting of:

[0422] (I) at least one oligomeric form;

[0423] (II) more than one oligomeric form;

[0424] (III) at least one oligomeric form and at least one monomeric form;

[0425] (IV) more than one oligomeric form and at least one monomeric form;

[0426] (V) at least one oligomeric form and more than one monomeric form; or

[0427] (VI) More than one oligomeric form and more than one monomeric form.

[0428] 103. A method comprising:

[0429] a) providing a blood sample from a subject;

[0430] b) isolating central nervous system ("CNS")-derived exosomes from a blood sample;

[0431] c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes;

[0432] d) isolating the inner contents of the scrubbed exosomes;

[0433] e) determining in the separated internal contents a quantitative measure of oligomeric α-synuclein and optionally one or more than one protein form selected from the group consisting of monomeric α-synuclein, phosphorylated α-synuclein, monomeric tau, oligomeric tau, phosphorylated tau, amyloid beta ("a-β") 1-40, amyloid beta 1-42, and oligomeric amyloid beta;

[0434] f) separating the species of oligomeric α-synuclein into more than one fraction;

[0435] g) determining a quantitative measure of each of one or more than one isolated oligomeric α-synuclein species and optionally one or more than one species selected from the group consisting of monomeric α-synuclein, tau-synuclein copolymers, amyloid β-synuclein copolymers, and tau-amyloid β-synuclein copolymers.

[0436] 104. A method according to embodiment 103, wherein the blood sample is a plasma sample.

[0437] 105. A method according to embodiment 103, wherein the blood sample comprises between about 5 ml and 20 ml of blood.

[0438] 106. The method of embodiment 103, wherein the subject is a human subject.

[0439] 107. The method of embodiment 106, wherein the subject has a synucleinopathy (e.g., Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy).

[0440] 108. The method of embodiment 103, wherein isolating CNS-derived exosomes comprises: (i) isolating total exosomes from a blood sample, and (ii) isolating CNS-derived exosomes from the total exosomes.

[0441] 109. The method of embodiment 103, wherein isolating CNS-derived exosomes comprises:

[0442] (i) ultracentrifugation;

[0443] (ii) density gradient centrifugation; or

[0444] (iii) Size Exclusion Chromatography.

[0445] 110. The method of embodiment 103, wherein isolating CNS-derived exosomes comprises capturing CNS-derived exosomes using a binding moiety that binds to a CNS-specific protein.

[0446] 111. The method of embodiment 110, wherein the CNS-specific protein is LCAM.

[0447] 112. A method according to embodiment 103, wherein removing proteins from the surface of the isolated exosomes comprises washing the isolated exosomes with an aqueous solution (e.g., phosphate buffered saline ("PBS")).

[0448] 113. A method according to embodiment 103, wherein the quantitative measurement is the total amount of protein form.

[0449] 114. A method according to embodiment 103, which includes determining a quantitative measurement of monomeric α-synuclein in the isolated internal contents.

[0450] 115. A method according to embodiment 103, which includes determining a quantitative measurement of one or more species selected from monomeric tau, oligomeric tau and phosphorylated tau in the isolated internal contents.

[0451] 116. The method of embodiment 103, comprising determining p129 α-synuclein.

[0452] 117. The method of embodiment 103, comprising determining in the separated internal contents a quantitative measurement of one or more species selected from amyloid β 1-40, amyloid β 1-42, and oligomeric amyloid β.

[0453] 118. A method according to embodiment 103, wherein separating the species into more than one fraction comprises separation by electrophoresis.

[0454] 119. A method according to embodiment 103, wherein separating the species into more than one fraction comprises separation by chromatography.

[0455] 120. A method according to embodiment 103, which includes determining at least one oligomeric form of α-synuclein in a separated species, wherein the at least one oligomeric form is selected from forms having between 2 and about 100 monomer units, between 4 and 16 monomer units, and no more than about 30 monomer units.

[0456] 121. A method according to embodiment 103, which includes determining a quantitative measurement of monomeric α-synuclein in an isolated species.

[0457] 122. A method according to embodiment 103, which includes determining quantitative measurements of more than one different oligomeric α-synuclein species in the separated species.

[0458] 123. A method according to embodiment 103, which includes determining a quantitative measurement of a copolymer comprising α-synuclein and tau in a separated species.

[0459] 124. A method according to embodiment 103, which includes determining a quantitative measurement of a copolymer comprising α-synuclein and amyloid β in a separated species.

[0460] 125. A method according to embodiment 103, wherein determining a quantitative measurement in a separated species includes detecting one or more than one separated species by immunoassay.

[0461] 126. A method according to embodiment 124, wherein the immunoassay comprises immunoblotting.

[0462] 127. The method of embodiment 124, wherein the immunoassay comprises protein blot.

[0463] 128. A method according to embodiment 124, wherein the immunoassay uses an antibody coupled to a direct label.

[0464] 129. A method according to embodiment 124, wherein the immunoassay uses an antibody coupled to an indirect marker.

[0465] 130. The method according to embodiment 103, further comprising:

[0466] f) determining a diagnosis of Parkinson's disease in the subject based on the quantitative measurement of the one or more isolated oligomeric alpha-synuclein species.

[0467] 131. The method according to embodiment 103, further comprising:

[0468] f) determining the quantitative amount of the protein in the subject before and after administration of the putative neuroprotective agent; and

[0469] g) determining a change in the amount of a protein or a pattern of a biomarker profile, wherein a change toward a normal amount or profile is indicative of the efficacy of the neuroprotective agent.

[0470] 132. The method according to embodiment 103, further comprising:

[0471] f) determining the quantitative amount of the protein in the subject at two different times; and

[0472] g) determining a change in the amount of a protein or a pattern of a biomarker profile, wherein the change is indicative of a change in a neurodegenerative state.

[0473] 133. A method comprising:

[0474] a) providing a sample comprising a mixture of proteins consisting essentially of proteins from the internal compartment of CNS-derived exosomes;

[0475] b) fractionating oligomeric α-synuclein species in the sample; and

[0476] c) determining a quantitative measure of each of one or more than one isolated oligomeric α-synuclein species and optionally one or more than one species selected from the group consisting of monomeric α-synuclein, tau-synuclein copolymers, amyloid β-synuclein copolymers, and tau-amyloid β-synuclein copolymers.

[0477] 134. The method of embodiment 133, wherein the product comprises oligomeric α-synuclein species isolated from a product enriched for scrubbed, CNS-derived exosomes. Example

[0478] The following examples are offered by way of illustration and not by way of limitation.

[0479] Example 1: In synucleinopathic conditions, α-synuclein oligomers are elevated compared to α-synuclein monomers

[0480] The subjects of the study are groups of individuals who have been diagnosed with synuclein pathological conditions and are given active therapeutic interventions and then given different, possibly known to be inactive therapeutic interventions or vice versa. Alternatively, the subjects of the study are groups of more than one subject who are asymptomatic for synuclein pathological conditions among more than one subject who have been diagnosed with synuclein pathological conditions. In either case, venous blood samples are collected from each subject by venipuncture at different times, including collection under baseline or control (e.g., inactive intervention treatment) conditions and collection again during the administration of potential active (e.g., experimental intervention) treatment. Exosomes derived from CNS are separated from blood using the methods described herein. The amount of monomeric α-synuclein and oligomeric α-synuclein or its specific species contained in the separated exosomes is measured. The ratio of oligomeric α-synuclein species relative to monomeric α-synuclein is determined. The results show that in a cohort of subjects diagnosed with synucleinopathy conditions, the ratio of oligomeric alpha-synuclein to monomeric alpha-synuclein was increased to a statistically significant degree. Those found to have significant changes in the results of this biomarker assay were later found to have proportional changes in clinical status.

[0481] Example 2: Subject Stratification / Clinical Trial

[0482] Volunteer subjects without PD and with PD are tested to determine the relative amounts of oligomeric α-synuclein and monomeric α-synuclein in CNS-derived exosomes. Based on the determined relative amounts and using the cutoff values ​​determined in the above examples, the subjects are clustered into several test groups. Some test groups are given placebos. In clinical trials, other test groups are administered different amounts of compounds. During and / or after administration, the test is repeated. The collected measurements are analyzed. It is determined that the therapeutic intervention produces a statistically significant decrease in the relative amount of oligomeric α-synuclein relative to monomeric α-synuclein.

[0483] Example 3: Clinical trial of a drug candidate with neuroprotective effects on synucleinopathies

[0484] The goal of the Phase II study is to evaluate the safety, tolerability and initial efficacy of pramipexole and, optionally, lovastatin or a similarly effective drug in patients with PD and related disorders, with pramipexole administered with aprepitant and with or without lovastatin. A sequential treatment, ascending dose, crossover, outpatient trial was conducted in up to 30 patients with PD (PD), multiple system atrophy (MSA), Lewy body dementia (LBD) or related synucleinopathy disorders. During the 3 months prior to entering the study, none of the participants were allowed to be treated with dopamine agonists or other centrally active drugs, except for levodopa-carbidopa (Sinemet), which was maintained at a stable dose at a level considered medically acceptable throughout the trial. After baseline clinical and laboratory assessments, including the Unified PD Rating Scale (UPDRS-Part III) and synuclein biomarkers, consenting individuals who met the inclusion criteria were switched from their pre-study PD treatment regimen to a regimen including pramipexole ER and aprepitant. Pramipexole ER doses are titrated to the best tolerated dose (or a maximum of 9 mg / day), and then stabilized for up to about 12 to 16 weeks. Then, combined therapy with additional drugs (e.g., statins) given at their maximum approved doses may be initiated for an additional 3 months as clinically appropriate, at which point all subjects return to their pre-hospital treatment regimen. During the trial, baseline efficacy and safety measurements, including determination of synuclein biomarker levels, are repeated at regular intervals. Efficacy is determined as a function of statistically significant changes in the biomarker profile of oligomeric alpha-synuclein and optionally monomeric alpha-synuclein species to normal.

[0485] Example 4: Diagnosis

[0486] The subject exhibits certain symptoms consistent with PD, but still lacks many of the significant clinical features of the disease at the preclinical level. Blood is collected from the subject by venipuncture. The amount of oligomeric α-synuclein and monomeric α-synuclein is measured from CNS-derived exosomes in the blood. A biomarker profile is determined. A diagnostic algorithm classifies the profile as consistent with a diagnosis of PD. The subject is diagnosed with PD and is placed on a treatment regimen that is either palliative therapy to relieve symptoms or treatment directed to the etiology of the disease for the purpose of neuroprotection.

[0487] Example 5: Staging

[0488] The subject presents with a diagnosis of PD. The physician orders a blood test for the subject to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. Based on the biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein, the physician determines that the subject is in an early stage of PD and is therefore more responsive to a specific therapeutic intervention.

[0489] Example 6: Prognosis / Progression

[0490] The subject is presented with a diagnosis of PD. The doctor orders a first blood test and a second blood test to be performed on the subject several months apart to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. Based on the biomarker profile of oligomeric α-synuclein relative to monomeric α-synuclein, the doctor determines that the subject's disease progression is slow and the subject is expected to have many years of useful life even without risky therapeutic intervention.

[0491] Example 7: Risk Assessment

[0492] The subject presents no symptoms of synuclein disease upon physical examination. In this case, the individual is aware of genetic or environmental risk factors. The physician orders a blood test for the subject to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. Based on a relatively abnormal biomarker profile of some or all measurable species of oligomeric α-synuclein compared to healthy control individuals, the physician determines that the subject has a low probability of developing PD.

[0493] Example 8: Response to Therapy

[0494] The subject presents with a diagnosis of PD. The physician orders an initial blood test for the subject prior to the start of treatment to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. After a round of treatment, but before a change in clinical symptoms, the physician orders a second blood test. Based on the change toward normal, the physician determines whether the treatment is effective or whether the dose needs to be changed or repeated.

[0495] Example 9: Development of diagnostics

[0496] Volunteer subjects without PD and with PD at different diagnostic stages are tested to determine a biomarker profile comprising more than one oligomeric α-synuclein and monomeric α-synuclein. Based on the determined biomarker profile, the subject is classified as showing the presence or absence of disease, and optionally the stage of disease. The profile is determined using a computerized learning algorithm that generates a classification algorithm for inferring the diagnosis after data analysis. The inference model is selected to produce a test with the desired sensitivity and specificity.

[0497] Example 10: α-Synuclein Oligomer Profile is Altered in Synucleinopathic Conditions

[0498] The individual groups of subjects of the study have been diagnosed with synuclein pathological conditions. The subjects are given an active therapeutic intervention and then given a different therapeutic intervention that may be known to be inactive. Alternatively, the intervention can be given in the opposite order. Alternatively, the subjects of the study are groups of more than one subject who are asymptomatic for the synuclein pathological conditions among more than one subject who has been diagnosed with the synuclein pathological conditions. In either case, venous blood samples are collected from each subject by venipuncture at different times, including collection under baseline or control (e.g., inactive intervention treatment) conditions and collection again during the administration of potentially active (e.g., experimental intervention) treatment. Exosomes derived from CNS are separated from blood using the methods described herein. The amount of more than one α-synuclein form of monomeric α-synuclein and oligomeric α-synuclein contained in the separated exosomes is measured. These data are combined into a data set. In this case, a statistical method for training a learning algorithm, such as a support vector machine, is used to analyze the data set to develop a model that infers whether a subject should be classified as having or not having a synuclein pathological condition. The results show that in a cohort of subjects diagnosed with a synuclein pathological condition, certain species of oligomeric alpha-synuclein are increased to a statistically significant degree relative to other oligomeric species and optionally monomeric species. Those that were found to have significant changes in the results of the biomarker assay were later found to have proportional changes in clinical status.

[0499] Example 11: Subject Stratification / Clinical Trial

[0500] Volunteer subjects without PD and with PD are tested to determine the biomarker profiles of oligomeric α-synuclein and optionally monomeric α-synuclein in CNS-derived exosomes. Based on the determined biomarker profiles and using the classifiers determined in the above embodiments, the subjects are clustered into several test groups. Some test groups are given placebos. Other test groups are administered different amounts of compounds in clinical trials. During administration and optionally after administration, the test is repeated. The collected measurements are analyzed. It is determined that the therapeutic intervention produces a statistically significant change to normal in the biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein.

[0501] Example 12: Clinical Trial of Drug Candidates with Neuroprotective Effects on Synucleinopathies

[0502] The goal of the Phase II study is to evaluate the safety, tolerability and initial efficacy of pramipexole and optionally lovastatin or similarly effective drugs in patients with PD and related disorders, pramipexole is given with aprepitant and with or without lovastatin. Up to 30 patients with PD (PD), multiple system atrophy (MSA), Lewy body dementia (LBD) or related synucleinopathy disorders are treated sequentially, with increasing doses, crossover, and outpatient trials. During the 3 months before study entry, none of the participants were allowed to be treated with dopamine agonists or other centrally active drugs, except for levodopa-carbidopa (Sinemet), which was maintained at a stable dose that was considered medically acceptable throughout the trial. After baseline clinical and laboratory assessments (including the Unified PD Rating Scale (UPDRS-Part III) and synuclein biomarker determination), consenting individuals who met the inclusion criteria were switched from their pre-study PD treatment regimen to a regimen including pramipexole ER and aprepitant. Pramipexole ER doses are titrated to the best tolerated dose (or a maximum of 9 mg / day), and then stabilized for up to about 12 to 16 weeks. Then, combined therapy with additional drugs (e.g., statins) given at their maximum approved doses may be initiated for an additional 3 months as clinically appropriate, at which point all subjects return to their pre-hospital treatment regimen. During the trial, baseline efficacy and safety measurements, including determination of synuclein biomarker levels, are repeated at regular intervals. Efficacy is determined as a function of statistically significant changes to normal in the biomarker profile comprising oligomeric alpha-synuclein and optionally monomeric alpha-synuclein species.

[0503] Example 13: Diagnosis

[0504] The subject exhibits certain symptoms consistent with PD, but still lacks many of the significant clinical features of the disease at the preclinical level. Blood is collected from the subject by venipuncture. The amount of oligomeric α-synuclein and monomeric α-synuclein is measured from CNS-derived exosomes in the blood. A biomarker profile is determined. A diagnostic algorithm classifies the profile as consistent with a diagnosis of PD. The subject is diagnosed with PD and is placed on a treatment regimen, either palliative therapy to relieve symptoms or treatment directed to the etiology of the disease for the purpose of neuroprotection.

[0505] Example 14: Staging

[0506] The subject presents with a diagnosis of PD. The physician orders a blood test for the subject to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. Based on the biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein, the physician determines that the subject is in an early stage of PD and is therefore more responsive to a specific therapeutic intervention.

[0507] Example 15: Prognosis / Progression

[0508] The subject is presented with a diagnosis of PD. The physician orders a first blood test and a second blood test of the subject several months apart to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. Based on the biomarker profile of oligomeric α-synuclein relative to monomeric α-synuclein, the physician determines that the subject's disease progression is slow and the subject is expected to have many years of useful life even without risky therapeutic intervention.

[0509] Example 16: Risk Assessment

[0510] The subject presents no symptoms of synuclein disease upon physical examination. In this case, the individual is aware of genetic or environmental risk factors. The physician orders a blood test for the subject to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. Based on the relatively abnormal biomarker profile of some or all measurable species of oligomeric α-synuclein compared to healthy control individuals, the physician determines that the subject has a low probability of developing PD.

[0511] Example 17: Response to Therapy

[0512] The subject presents with a diagnosis of PD. The physician orders an initial blood test for the subject prior to the start of treatment to determine a biomarker profile comprising oligomeric α-synuclein and optionally monomeric α-synuclein. After a round of treatment, but before a change in clinical symptoms, the physician orders a second blood test. Based on the change toward normal, the physician determines whether the treatment is effective or whether a change or repeat of the dose is required.

[0513] Example 18: Exemplary Biomarker Profiles

[0514] Figure 7 An exemplary biomarker spectrum is shown, including monomeric species of alpha-synuclein and five oligomeric species in five different states. States include normal, Parkinson's disease stage 1 (PD-1), Parkinson's disease stage 2 (PD-2), treatment with therapeutic agent 1 (Rx-1), and treatment with therapeutic agent 2 (Rx-2). The relative amount of each of the oligomeric species is represented by the darkness of the line. As can be seen, oligomer 4 is increased in both stage 1 Parkinson's disease and stage 2 Parkinson's disease. In contrast, oligomer 1, oligomer 2, and oligomer 3 are increased in stage 1, but not in stage 2. Therapeutic agent 1 reduces the relative amount of oligomer 4 and is considered to have neuroprotective activity. In contrast, therapeutic agent 2 does not reduce the relative amount of oligomer 4, and in this embodiment, it is considered not to have a neuroprotective effect.

[0515] Example 19: Development of diagnostics for Alzheimer's disease

[0516] Volunteer subjects diagnosed by medical professionals as having Alzheimer's disease or not having Alzheimer's disease provided blood samples for testing. The internal contents of brain-derived exosomes were separated. The amount of each of more than one species of monomeric a-β and oligomeric a-β was determined. Comparison of the results showed that in subjects diagnosed with Alzheimer's disease, one oligomeric form continued to increase compared to monomeric a-β. It was further determined that the amount of this form above a determined threshold level provided a diagnosis of Alzheimer's disease with 85% sensitivity and 98% specificity. This threshold level was used to diagnose other subjects with Alzheimer's disease.

[0517] Example 20: Advances in the diagnosis of Huntington's disease

[0518] Volunteer subjects diagnosed by medical professionals as having Huntington's disease or not having Huntington's disease provided blood samples for testing. The internal contents of brain-derived exosomes were isolated. The amount of each of more than one species of oligomeric huntingtin protein was determined. Using linear regression analysis, it was found that the amount of the three individual oligomeric forms combined could be diagnostic of Huntington's disease in the form of a linear mathematical model.

[0519] As used herein, unless otherwise specified, the following meanings apply. The word "may" is used in a permissive sense (i.e., meaning possible), rather than a mandatory sense (i.e., meaning must). The words "include / include (include)", "include / include (including)" and "includes / includes (includes)" etc. mean including / including but not limited to. The singular forms "a", "a" and "the" include plural indicators. Thus, for example, referring to "an element" includes a combination of two or more elements, although other terms and expressions, such as "one or more" are used for one or more elements. Unless otherwise specified, the term "or" is non-exclusive, that is, covers both "and" and "or". The term "any one of..." between a modifier and a sequence means each member in the modifier modification sequence. Thus, for example, the expression "at least one of 1, 2 or 3" means "at least 1, at least 2 or at least 3". The expression "at least one" includes "more than one". The term "consisting essentially of" means comprising the recited elements and other elements that do not materially affect the basic and novel characteristics of the claimed combination.

[0520] Although certain embodiments of the present invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided only by way of example. Without departing from the present invention, those skilled in the art will now expect many variations, changes and replacements. It should be understood that a variety of alternatives of the embodiments of the present invention described herein may be adopted in practicing the present invention. The appended claims are intended to define the scope of the present invention, and thus encompass methods and structures and their equivalents within the scope of these claims.

[0521] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Claims

1. A kit for quantitatively measuring one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms of alpha-synuclein, formulated for carrying out a method comprising: a) providing a blood sample from a subject; b) isolating central nervous system ("CNS")-derived exosomes from the blood sample; c) removing proteins from the surface of the isolated exosomes to produce scrubbed exosomes; d) isolating the inner contents of the scrubbed exosomes; e) separating species of oligomeric α-synuclein from said separated internal contents into more than one fraction; f) determining a quantitative measurement of the one or more isolated oligomeric α-synuclein species using one or more antibodies that recognize α-synuclein.

2. The kit according to claim 1, wherein the blood sample is a plasma sample.

3. The kit according to claim 1, wherein the blood sample comprises between 5 ml and 20 ml of blood.

4. The kit of claim 1, wherein the subject is a human subject.

5. The kit of claim 4, wherein the subject suffers from a synucleinopathy.

6. The kit of claim 5, wherein the synucleinopathy is selected from Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

7. The kit according to claim 1, wherein isolating CNS-derived exosomes comprises: (i) isolating total exosomes from the blood sample, and (ii) isolating CNS-derived exosomes from the total exosomes.

8. The kit according to claim 1, wherein isolating CNS-derived exosomes comprises: (i) Ultracentrifugation; (ii) density gradient centrifugation; or (iii) Size exclusion chromatography. 9 . The kit of claim 1 , wherein isolating CNS-derived exosomes comprises capturing the CNS-derived exosomes using a binding moiety that binds to a CNS-specific protein.

10. The kit according to claim 9, wherein the CNS-specific protein is LCAM.

11. The kit of claim 1, wherein removing proteins from the surface of the isolated exosomes comprises washing the isolated exosomes with phosphate buffered saline ("PBS").

12. The kit of claim 1, said method comprising determining a quantitative measure of monomeric alpha-synuclein in said isolated internal contents.

13. The kit of claim 1, said method comprising determining in said isolated internal contents a quantitative measurement of one or more species selected from monomeric tau, oligomeric tau, and phosphorylated tau.

14. The kit of claim 1, wherein the method comprises determining p129 alpha-synuclein.

15. The kit of claim 1, said method comprising determining in said separated internal contents a quantitative measurement of one or more species selected from the group consisting of amyloid beta 1-40, amyloid beta 1-42 and oligomeric amyloid beta.

16. The kit of claim 1, wherein separating the species into more than one fraction comprises separation by electrophoresis.

17. The kit of claim 1, wherein separating the species into more than one fraction comprises separation by chromatography.

18. The kit of claim 1, wherein the method comprises determining in the isolated species at least one oligomeric form of alpha-synuclein, the at least one oligomeric form selected from the group consisting of a form having between 2 and 100 monomeric units, between 4 and 16 monomeric units, and not more than 30 monomeric units.

19. The kit of claim 1, wherein the method comprises determining a quantitative measurement of monomeric alpha-synuclein in the isolated species.

20. The kit of claim 1, wherein the method comprises determining the quantitative measurement of more than one different oligomeric alpha-synuclein species in the separated species.

21. The kit of claim 1, the method comprising determining a quantitative measure of a copolymer comprising alpha-synuclein and tau in the isolated species.

22. The kit of claim 1, the method comprising determining a quantitative measure of a copolymer comprising alpha-synuclein and amyloid beta in the isolated species.

23. The kit of claim 1, wherein determining a quantitative measurement in the separated species comprises detecting one or more than one separated species by immunoassay.

24. The kit of claim 23, wherein the immunoassay comprises an immunoblot.

25. The kit of claim 23, wherein the immunoassay comprises a Western blot.

26. The kit of claim 23, wherein the immunoassay uses an antibody conjugated to a direct label.

27. The kit of claim 23, wherein the immunoassay uses an antibody conjugated to an indirect label.

28. The kit of claim 1, further comprising: g) determining a diagnosis of Parkinson's disease in said subject based on said quantitative measurement of one or more isolated oligomeric alpha-synuclein species.

29. The kit according to claim 1, further comprising: g) determining the quantitative amount of the protein in the subject before and after administration of the putative neuroprotective agent; as well as h) determining a change in the amount of a protein or a pattern of a biomarker profile, wherein a change toward a normal amount or profile is indicative of the efficacy of the neuroprotective agent.

30. The kit of claim 1, further comprising: g) determining the quantitative amount of a protein in said subject at two different times; as well as h) determining a change in the amount of a protein or a pattern of a biomarker profile, wherein the change is indicative of a change in a neurodegenerative state.

31. A method comprising: a) enriching each blood sample in a collection of blood samples for brain-derived exosomes, wherein: (i) said collection of blood samples is from subjects in a cohort of subjects, wherein said cohort comprises subjects comprising: (1) more than one subject diagnosed with a synucleinopathy condition, each at more than one different disease stage, wherein each of the diagnosed subjects has received a putative neuroprotective agent, and / or (2) More than one healthy control subject, wherein the blood sample is collected prior to administration of the putative neuroprotectant and again one or more times during administration of the putative neuroprotectant, and optionally after administration of the putative neuroprotectant; b) isolating protein contents from the internal compartment of exosomes to generate biomarker samples; c) measuring the amount of each of one or more than one neurodegenerative protein forms in the biomarker sample to create a data set, wherein the neurodegenerative protein forms include one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms; and d) performing statistical analysis on said dataset to: (i) comparing the amount of each of said neurodegenerative protein forms in individual subjects over time to determine a diagnostic algorithm that predicts the rate of disease progression or the degree of response to said putative neuroprotective agent; or (ii) comparing the differences in the amounts of each of the neurodegenerative protein forms between different subjects to determine a diagnostic algorithm that (1) makes an etiological diagnosis, (2) separates subgroups of clinically similar but etiologically distinct synucleinopathy conditions, or (3) predicts whether or to what extent a subject is likely to respond to the putative neuroprotective agent.

32. A kit for quantitatively measuring one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms of alpha-synuclein, formulated for carrying out a method comprising: a) enriching brain-derived exosomes from a blood sample of a subject; b) isolating protein contents from the internal compartment of exosomes to generate biomarker samples; c) measuring the amount of each of one or more than one neurodegenerative protein forms in the biomarker sample to create a neurodegenerative protein profile, wherein the neurodegenerative protein forms include one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms; as well as d) correlating the neurodegenerative protein profile to either: (1) make an etiological diagnosis, or (2) classify the subject into one of more than one subgroup of clinically similar but etiologically distinct synucleinopathy conditions.

33. A method comprising: a) providing, for each of more than one subject, a dataset comprising values ​​indicative of: (1) the status of a synucleinopathy condition, and (2) a quantitative measure of the amount of each of one or more than one neurodegenerative protein forms in a blood sample enriched for CNS-derived microsomal particles, wherein the neurodegenerative protein forms include one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms; as well as b) performing a statistical analysis on said dataset to develop a model for inferring the status of said synucleinopathy condition in an individual.

34. Use of an agent for quantitatively measuring one or more neurodegenerative protein forms and optionally one or more monomeric forms in the preparation of a kit for inferring the risk of development, diagnosis, staging, prognosis or progression of a synucleinopathy condition characterized by oligomeric alpha-synuclein forms by performing a method comprising: a) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms include one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms; and b) performing a model on the dataset to infer the risk of development, diagnosis, staging, prognosis or progression of the synucleinopathy condition.

35. Use of an agent for quantitatively measuring one or more neurodegenerative protein forms and optionally one or more monomeric forms in the preparation of a kit for determining the effectiveness of a therapeutic intervention in treating a synucleinopathy condition characterized by oligomeric alpha-synuclein forms by performing a method comprising: (a) In each subject in a population comprising more than one subject, inferring the initial state of the synucleinopathy condition by: (1) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms include one or more oligomeric forms of α-synuclein and optionally one or more monomeric forms; as well as (2) using the model to infer the initial state; (b) after inferring, administering said therapeutic intervention to said subject; (c) after administration, inferring the subsequent status of the synucleinopathy condition in each individual subject in the population by: (1) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms and optionally one or more monomeric forms; as well as (2) using the model to infer the subsequent state; and (d) based on the initial inference and the subsequent inference in the population, determining that the therapeutic intervention is effective if the subsequent inference presents a statistically significant change toward a normal state compared to the initial inference, or determining that the therapeutic intervention is not effective if the subsequent inference does not present a statistically significant change toward a normal state compared to the initial inference.

36. Use of an agent for quantitatively measuring one or more oligomeric forms and optionally one or more monomeric forms of oligomeric alpha-synuclein in the preparation of a kit for use in a clinical trial for admitting a subject to a therapeutic intervention for treating or preventing a synucleinopathy condition by performing a method comprising: a) The subject is determined to be abnormal with respect to a synucleinopathy condition characterized by oligomeric alpha-synuclein forms by: i) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms include one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms; as well as ii) performing a model on the profile to infer that the subject is abnormal with respect to the synucleinopathy condition; and c) enrolling said subject in said clinical trial for a potential therapeutic intervention for said synucleinopathy condition.

37. Use of an agent for quantitatively measuring one or more neurodegenerative protein forms and optionally one or more monomeric forms in the preparation of a kit for monitoring a subject's progress towards a therapeutic intervention for a synucleinopathy condition by performing a method comprising: (a) inferring the initial state of the synucleinopathy condition in the subject by: (1) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms include one or more oligomeric forms of α-synuclein and optionally one or more monomeric forms; as well as (2) executing the model to infer the initial state of the synucleinopathy condition; (b) after inferring, administering said therapeutic intervention to said subject; (c) after administration, inferring a subsequent status of the synucleinopathy condition in the subject by: (1) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms include one or more oligomeric forms of α-synuclein and optionally one or more monomeric forms; as well as (2) executing the model to infer subsequent states of the synucleinopathy condition; (d) based on the initial state inference and the subsequent state inference, if the subsequent inference shows a change toward a normal state compared to the initial inference, determining that the subject has a positive response to the therapeutic intervention, or if the subsequent inference does not show a change toward a normal state compared to the initial inference, determining that the therapeutic intervention is not effective.

38. Use of an agent for quantitatively measuring one or more neurodegenerative protein forms and optionally one or more monomeric forms in the preparation of a kit for inferring the risk of development, diagnosis, staging, prognosis or progression of a synucleinopathy condition characterized by oligomeric alpha-synuclein forms by performing a method comprising: a) determining a neurodegenerative protein profile from a blood sample from a subject enriched for CNS-derived microsomal particles to create a data set, the neurodegenerative protein profile comprising quantitative measurements of each of one or more than one neurodegenerative protein forms, wherein the neurodegenerative protein forms comprise one or more oligomeric forms of alpha-synuclein and optionally one or more monomeric forms; as well as b) correlating said oligomeric alpha-synuclein profile with risk of development, diagnosis, staging, prognosis or progression of said synucleinopathic condition.

39. The kit of claim 1, comprising determining a quantitative measurement of an oligomeric alpha-synuclein species selected from: (I) at least one oligomeric form comprising a single oligomeric species; (II) at least one oligomeric form comprising a collection of oligomeric species; (III) at least one oligomeric form and at least one monomeric form; (IV) multiple oligomeric forms and at least one monomeric form; (V) at least one oligomeric form and a plurality of monomeric forms; and (VI) Multiple oligomeric forms and multiple monomeric forms.

40. The kit of claim 1, wherein the toxic oligomeric species measured comprises a collection of oligomeric alpha-synuclein species.

41. The kit of claim 1, wherein the toxic oligomeric form comprises an alpha-synuclein oligomer comprising up to 30 monomeric units.

42. The kit of claim 1, wherein the blood sample comprises a venous plasma sample.

43. The kit of claim 1, comprising specifically measuring a toxic oligomeric alpha-synuclein species selected from the group consisting of 10-mer, 11-mer, 12-mer, 13-mer, 14-mer, 15-mer, 16-mer and 18-mer.

44. The kit of claim 1, wherein one of the forms of toxic oligomeric alpha-synuclein measured is a collection of species ranging from 4-mer to 16-mer.

45. The kit of claim 1, further comprising measuring one or more species selected from the group consisting of monomeric α-synuclein, tau-synuclein copolymers, amyloid β-synuclein copolymers, and tau-amyloid β-synuclein copolymers.

46. ​​The kit of claim 32, wherein the blood sample is a plasma sample.

47. The kit of claim 32, wherein the blood sample comprises 5 ml to 20 ml of blood.

48. The kit of claim 32, wherein the subject is a human subject.

49. The kit of claim 48, wherein the subject has a synucleinopathy.

50. The kit of claim 49, wherein the synucleinopathy is selected from Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

51. The kit of claim 32, wherein isolating CNS-derived exosomes comprises: (i) isolating total exosomes from blood samples, and (ii) isolating CNS-derived exosomes from total exosomes.

52. The kit of claim 32, wherein isolating CNS-derived exosomes comprises: (i) Ultracentrifugation; (ii) density gradient centrifugation; or (iii) Size exclusion chromatography.

53. The kit of claim 32, wherein isolating CNS-derived exosomes comprises capturing CNS-derived exosomes using a binding moiety that binds to a CNS-specific protein.

54. The kit of claim 53, wherein the CNS-specific protein is LCAM.

55. The kit of claim 32, wherein removing proteins from the surface of the isolated exosomes comprises washing the isolated exosomes with phosphate buffered saline ("PBS").

56. The kit of claim 32, comprising determining a quantitative measurement of monomeric alpha-synuclein in the isolated internal contents.

57. The kit of claim 32, comprising determining in the isolated internal contents a quantitative measurement of one or more species selected from monomeric tau, oligomeric tau, and phosphorylated tau.

58. The kit of claim 32, comprising determining p129 alpha-synuclein.

59. The kit of claim 32, comprising determining in the separated internal contents a quantitative measurement of one or more species selected from the group consisting of amyloid beta 1-40, amyloid beta 1-42, and oligomeric amyloid beta.

60. The kit of claim 32, wherein separating the species into more than one fraction comprises separation by electrophoresis.

61. The kit of claim 32, wherein separating the species into more than one fraction comprises separation by chromatography.

62. The kit of claim 32, comprising determining in the isolated species at least one oligomeric form of alpha-synuclein, said at least one oligomeric form being selected from forms having between 2 and 100 monomeric units, between 4 and 16 monomeric units, and not more than 30 monomeric units.

63. The kit of claim 32, comprising determining a quantitative measurement of monomeric alpha-synuclein in an isolated species.

64. The kit of claim 32, comprising determining the quantitative measurement of more than one different oligomeric alpha-synuclein species in the isolated species.

65. The kit of claim 32, comprising determining a quantitative measurement of a copolymer comprising alpha-synuclein and tau in an isolated species.

66. The kit of claim 32, comprising determining a quantitative measurement of a copolymer comprising alpha-synuclein and amyloid beta in an isolated species.

67. The kit of claim 32, wherein determining a quantitative measurement in the separated species comprises detecting one or more than one separated species by immunoassay.

68. The kit of claim 67, wherein the immunoassay comprises an immunoblot.

69. The kit of claim 67, wherein the immunoassay comprises a Western blot.

70. The kit of claim 67, wherein the immunoassay uses an antibody conjugated to a direct label.

71. The kit of claim 67, wherein the immunoassay uses an antibody conjugated to an indirect label.

72. The kit of claim 32, further comprising: g) determining the quantitative amount of the protein in the subject before and after administration of the putative neuroprotective agent; as well as h) determining a change in the amount of a protein or the pattern of the biomarker profile, wherein a change toward a normal amount or profile is indicative of the efficacy of the neuroprotective agent.

73. The kit of claim 32, further comprising: g) determining the quantitative amount of the protein in the subject at two different times; as well as h) determining a change in the amount of a protein or a pattern of a biomarker profile, wherein the change is indicative of a change in a neurodegenerative state.

74. The kit of claim 32, comprising determining a quantitative measurement of an oligomeric alpha-synuclein species selected from: (I) at least one oligomeric form comprising a single oligomeric species; (II) at least one oligomeric form comprising a collection of oligomeric species; (III) at least one oligomeric form and at least one monomeric form; (IV) multiple oligomeric forms and at least one monomeric form; (V) at least one oligomeric form and a plurality of monomeric forms; and (VI) Multiple oligomeric forms and multiple monomeric forms.

75. The kit of claim 32, wherein the toxic oligomeric species measured comprises a collection of species of oligomeric alpha-synuclein.

76. The kit of claim 32, wherein the toxic oligomeric form comprises an alpha-synuclein oligomer comprising up to 30 monomeric units.

77. The kit of claim 32, wherein the blood sample comprises a venous plasma sample.

78. The kit of claim 32, comprising specific measurement of toxic oligomeric alpha-synuclein species selected from the group consisting of 10-mer, 11-mer, 12-mer, 13-mer, 14-mer, 15-mer, 16-mer and 18-mer.

79. The kit of claim 32, wherein one of the forms of toxic oligomeric alpha-synuclein measured is a collection of species ranging from 4-mer to 16-mer.

80. The kit of claim 32, further comprising measuring one or more species selected from the group consisting of monomeric α-synuclein, tau-synuclein copolymers, amyloid β-synuclein copolymers, and tau-amyloid β-synuclein copolymers.